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Abstract
Amphetamine (AMPH) and its derivatives embody a remarkable breadth
of pharmacology. These molecules exert their effects, both therapeutic and
pathological, at the human monoamine transporters, which tune synaptic
dynamics by evacuating monoamine neuromodulators from the synapse
subsequent to neuronal impulses. These transporters are electrogenic, and the
transporter-mediated current can be correlated to a surrogate measure of the
change in membrane voltage: Ca++ currents from co-transfected L-type Ca++
channels. The present work makes use of this assay, with which it is possible to
derive pharmacodynamic metrics from both substrates and inhibitors. This work
presents data on a heretofore-unstudied class of amphetamine analogs: the
enantiomers of N-Me 4-Me AMPH and N-Et 4-Me AMPH. Remarkably, while both
enantiomers of the N-Me version of this compound function as substrates at
hDAT, both enantiomers of the N-Et version are inhibitors. This switch does not
occur at hNET, where all enantiomers of both N-Me and N-Et 4-Me AMPH
function as substrates. Further, (S)-N-Et 4-Me AMPH is a substrate at dDAT.
EC50 and IC50 values for all drugs at both transporters are presented. I present
the results of super-resolution microscopic co-localization studies on the
plasmalemmal spatial relation of the human dopamine transporter and voltage
gated calcium channel, L-type 1.2 (CaV1.2). I discuss future aims toward a
unified understanding of the mechanisms of monoamine transporter function,
with an emphasis on what amphetamine can illuminate in this regard.
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I. Introduction: Scientific foundations and significance
1. Physiology and Biophysics
The substrate of a single neuron represents an informational bottleneck:
despite the infinite complexity of widespread synaptic inputs, a neuron is
constrained by its anatomy to a restricted class of output down its single axon
(Tononi and Cirella, 2014). The neuron can be silent or spike, and, if spiking,
may modulate the frequency of spiking to encode additional information.
Chemicals dubbed neuromodulators regulate and tune the conductance
characteristics of neurons usually by means of G-protein coupled receptor
(GCPR)-mediated signaling cascades. Neuromodulators include acetylcholine;
short peptides; lipids; gases; and the biogenic amines: the catecholamines
(dopamine, epinephrine, and norepinephrine), and serotonin. In general, the
catecholamines function on a slower time scale, modulating the fast, ionotropic
networks of glutamatergic and GABAergic signaling. Norepinephrinergic
projections feed the cortex mainly from the locus coeruleus of the pons.
Meanwhile, dopaminergic projections arise from the substantia nigra to the
thalamus; from the ventral tegmental area to the nucleus accumbens and to the
prefrontal cortex; and from the arcuate nucleus of the hypothalamus to the
pituitary, modulating hormone secretion. Norepinephrine gives rise to
downstream signaling cascades via α1 (Gαq-coupled), α2 (Gαi-coupled), β1 (Gαscoupled), and β2 (Gαs-coupled) metabotropic receptors; dopamine via D1 and D5
receptors (Gαs-coupled) and via D2-D4 receptors (Gαi-coupled). Thus, the only
direct ionotropic effects mediated by dopamine and norepinephrine are at the
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dopamine and norepinephrine transporters themselves (please see rest of
Introduction). Please see Figure I1 for a schematic rendering of how
neuromodulators can control the behavior of downstream neurons.

Figure I1: Neuromodulators may:
A. modify the kinetics of
downstream action potentials; B.
change the temporal progression
of trains of single spikes; C.
silence or switch on neuronal
bursting; D. modulate the
neuronal response to a stimulus,
denoted by the arrow. Adapted
from Kaczmarek and Levitan
(1987), Figure 1.1.

The human monoamine transporters are 12-transmembrane helical,
perisynaptic and extrasynaptic (Hersch et al., 1997) integral membrane proteins
of presynaptic neuronal dendrites and axon. By means of the exploitation of the
Na+ concentration that exists across the plasmalemma, the transporters couple
the import of the monoamines from the extracellular fluid back into the cytoplasm
to the thermodynamically spontaneous flux of sodium. The cardinal function of
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these proteins—which include the dopamine transporter (DAT), the serotonin
transporter (SERT), and the norepinephrine transporter (NET)—is to tune the
neurocomputational effects of the neuromodulators dopamine, serotonin, and
norepinephrine. Each transporter belongs to the solute carrier family 6 class of
genes. Each is also classified as a member of the neurotransmitter:sodium
symporter family of transporters. When the human transporter isoform is
indicated, a lower-case h precedes the name of the transporter. FRET studies
have demonstrated that hDAT and hSERT exist as oligomeric complexes,
modeled as a dimer of dimers, within the membranes of living cells, while coimmunoprecipitation studies have evidenced the notion that hDAT, hSERT, and
hNET all exist in higher order quaternary structures (Sitte, 2003).
In addition to the transporter isoforms isolated from the human genome,
great insight into transporter function has arisen from study of the arthropod
congeners of these proteins, among them the serotonin transporter of Drosophila
melanogaster, dSERT; the dopamine transporter of Drosophila melanogaster,
dDAT; and the dopamine transporter of Caenorhabditis elegans, DAT-1. dDAT is
interesting in its possession of both hDAT- and hNET-like characteristics. While
dDAT transports tritiated dopamine with the highest affinity among the biogenic
amines, it shows the highest sensitivity to inhibitors of hNET (Pörzgen et al.,
2001). Indeed, the crystal structure of dDAT bound to nortriptyline, which shows
very low affinity for hDAT, has been solved (Penmasta et al., 2013). Like hDAT,
dDAT also demonstrates stereoselective differences in affinity between the (R)
and (S) enantiomers of AMPH and AMPH analogs. hNET does not show a
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differential affinity for the enantiomers of AMPH and AMPH analogs. Thus dDAT
likely represents a primordial catecholamine transporter and a common ancestor
of hDAT and hNET. hDAT and hNET likely diverged in function subsequent to a
gene duplication event (Pörzgen et al., 2001). Notably, dDAT permeates currents
of a greater magnitude than those of hDAT, and currents of 120nA are readily
observed. Please see Figure I2 for a structure of dDAT bound to N-Me AMPH
based on PDB 4XP6 from Wang et al., 2015.

Figure I2: Crystal structure of dDAT bound
to N-Me AMPH (cyan). Shown also are 2
bound Na+ ions (purple spheres). Image
constructed in UCSF Chimera with PDB
4XP6 from Wang et al., 2015. Note
dDAT’s characteristic shot glass-like
shape.

Classical experiments demonstrated that the uptake of substrate by
means of monoamine transporters was dependent on sodium and chloride, and,
in the case of the hSERT, internal potassium (Rudnick and Nelson, 1978).
Jardetzky (1966) popularized a simple model of high explanatory power to
imagine the isomerization of transporters as they execute the function of
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substrate uptake. In this model, dubbed the model of alternating access,
substrate binds the outward facing conformation of the transporter; then sodiumand chloride-mediated rearrangements of the transporter’s network of amino
acids gives rise to a conformational change that pushes the substrate binding
site to face the intracellular environment. The solution of the crystal structure for
dDAT (Penmasta et al., 2013; Wang et al., 2015) places 2 Na+ binding sites and
1 Cl- binding site in close proximity to the substrate binding pocket. Charged
portions of residues from transmembrane (TM) regions 1, 6, 7, and 8 coordinate
these ions. Diffusion of bound ions gives rise to a state of the transporter with a
low affinity for the substrate, which dislodges and effects a final rearrangement of
the transporter back to the outward facing state. Transport of dopamine by hDAT
is proposed to require the binding of 1-2 Na+ : 1 Cl-, and 1 dopamine+, while
hNET is proposed to require the binding of 1 Na+ : 1 Cl-, and 1 norepinephrine+.
Notably, for hSERT this model predicts that since the transport scheme consists
of 1 Na+ : 1 Cl- : and 1 serotonin+ exchanging for the counter-transport of 1 K+,
the transport cycle will be electroneutral.
The solution of the crystal structure of the prokaryotic leucine transporter,
LeuT, augmented the details of this model. LeuT is a member of the
neurotransmitter:sodium symporter family of proteins. LeuT shares about 20%
sequence homology to the human monoamine transporters, yet LeuT folds into
tridimensional motifs similar to those of the human monoamine transporters
(Zhou et al., 2007). There exists in LeuT—and in the crystal structure of the more
recently solved dDAT—a central cavity formed by networks of transmembrane
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helices at which the cognate substrates of these transporters crystallize. This site
has been termed the S1 site. Further, the LeuT crystal suggested a novel
transitory state of the transport cycle. Since the proposed portions of the protein
that mediate gating during the transport cycle move in tandem (Schmitt et al.,
2013), there is an intermediate conformational state between the outward-open
and inward-open state. This state is conceptualized as a dually-occluded state,
and putatively functions to prevent water infiltration of the S1 site during the
substrate translocation cycle. 11Å superior to the S1 site, in the area of the
extracellular vestibule of LeuT, there exists a site termed the S2 site. Binding by
substrate at this site is hypothesized to modulate the transport cycle, spurring the
transporter to isomerize from the dually-occluded state to the inward-facing
conformation (Schmitt et al., 2013).
Regarding monoamine transporter function, there exists a fascinating
breadth of function outside of the explanatory scope of the model of alternating
access. Hybridized to their canonical work in the control of synaptic dynamics by
means of reuptake, these proteins exhibit a mode of function analogous to the
classical ion channels. The channel-like mode of transporter function is
analogous to ion channel function over and above the more superficial fact that
transporters transduce the release of neurotransmitter to changes in the
membrane potential via the stoichiometric, sodium-dependent reuptake which the
model of alternating access offers (Sonders and Amara, 1998). Having measured
the turnover number of hNET at 1.7 norepinephrine molecules per transporter
per second, and having measured norepinephrine-induced current in the same

13
stably-transfected hNET cells held at -120mV, Galli, De Felice et al. (1995)
calculate that measured values for current amplitude exceed by orders of
magnitude the value expected if stoichiometric transporter cycling were the sole
ion path. Even after extrapolating to the amplitude of the current at -40mV, the
natural membrane potential of HEK293 cells and the potential at which uptake
experiments are conducted, the orders of magnitude value discrepancy remains.
Further, patch clamp experiments have measured distinct, brief, channel-like
events during which transporters permeate a magnitude of current similar to,
though less than, the order of that which permeates an ion channel. The work of
Galli, Blakely, and De Felice (1996) has established that at potentials of -60mV,
noise analysis reveals the existence of channel-like openings of hNET that carry
an inward current. Thus, the monoamine transporters have dissociable modes of
function, and various models have conceptualized these modes.
Much work has sought to parse out the various components of the current
that permeates a monoamine transporter and to unify the understanding of how
these components relate to the transport of substrate. Do the channel modes
carry substrate and other ions, or just other ions? In other words, is the channel
mode coupled to substrate transport? And: what is the relation between the
channel mode and the mode of classical stoichiometric cycling? Do channel
events represent a low-probability event co-occurring throughout the
stoichiometric cycle? Adams and De Felice (2003), using cut-open oocytes,
collect a substantial set of data in order to test a set of predictions that follow
from the model of alternating access. The group demonstrates various

14
inconsistencies between their measured electrophysiological data and the
predictions of the alternating access model. For example, the model of
alternating access predicts that elevations in the internal concentration of
serotonin result in a reduction in external serotonin-induced currents due to the
fact that by elevating internal serotonin, the equilibrium of the transport cycle is
shifted to favor the inward facing transporter. This effect of internal serotonin
does obtain through experimentation (Adams and De Felice, 2003). However,
Adams and De Felice (2003) note that external application of serotonin results in
the blockade of the leak current even when oocytes are exposed to elevated
concentrations of intracellular serotonin, implying that a portion of the SERT
population remains facing the external environment.
As an alternative, they suggest that a model in which serotonin and ions
file through a common pore may explain the bulk of their data. Dubbed flux
coupling, this concept explains the fact that internal serotonin reduces the
serotonin-induced current by positing that this internal serotonin effectively
occludes the permeation pore. Galli et al. (1997) expand on the possible
mechanisms of flux coupling. Via simultaneous measurement of current and
uptake in oocytes expressing the serotonin transporter of Drosophila
melanogaster (dSERT), Galli et al. (1997) use fluctuation analysis (estimation of
serotonin-induced current at -20mV) in conjunction with shot noise theory
(estimation of the amount of charge permeated per channel event) to calculate
the number of discrete serotonin transport events per channel event. This
estimation is possible by the calculation of two metrics: ρ = the number of

15
charges per serotonin molecule transported, which is known from the
measurement of uptake; and q = the net charge per channel event, derived from
shot noise theory. Having established values for these parameters, it is
calculated that, assuming serotonin-induced channel events are uncoupled to
transport, q/ρ = 458, a result that represents the number of transport cycles
occurring for each channel event. However, citing mutual sensitivity of uptake
and current to antagonist blockade along with mutual ionic requirements, the
authors suggest that transport and ion permeation during channel events are
coupled. Thus, the alternate interpretation for q/ρ becomes the number of
serotonin molecules transported per open channel event. Both interpretations are
offered as valid interpretations of the study’s data. Importantly, this study also
demonstrates that in dSERT, uptake of tritiated serotonin is significantly
correlated with negative values of the membrane potential. Curiously, the
correlation of substrate uptake with more hyperpolarized values of the membrane
potential obtains with hDAT (Saunders et al. 1997) but not with hSERT (Mager
1994).
Additional strong evidence for the notion that the function of transporters
depends in part on the permeation of relatively large, fast, ion channel-like
currents exists in the form of simultaneous studies of substrate uptake and
current in heterologous expression systems. Expanding on previous work
wherein first arose the idea that hNET harbors a ligand-gated ion-ligand channel,
Galli, Blakely, and De Felice (1998) perform microamperometry simultaneous to
inside-out patch clamping of stably transfected hNET cells in order to correlate
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current flux events with substrate transport. This 1998 study shows that at a
potential of -120mV, transporter-mediated norepinephrine flux, measured by
microamperometry assuming 3 oxidation events per norepinephrine molecule,
carries <1% of the total current. Crucially, the ratio of the current attributable to
norepinephrine to the total desipramine-sensitive current decreases as a function
of hyperpolarization. In other words, at more hyperpolarized membrane
potentials, a greater proportion of the hNET-mediated current is carried by ions
other than norepinephrine. Via the metric of the average Pearson product
moment between the amperometric current and the patch current, this work
further discovers a strong temporal correlation between single-channel events
and norepinephrine oxidation events.
Developing on the work with dSERT (Galli et al., 1997), Galli, Blakely, and
De Felice (1998) concludes with the recognition that two models follow from the
logic of the data: norepinephrine-gated single channel events mediate the
passage of a mixture of norepinephrine molecules and other ions via a common
permeation pathway, or a simultaneous transport mode and channel mode could
be “separate events that are linked by an allosteric mechanism.” Investigating
deeper, the group finds a strong correlation between the amount of elementary
charge passing through the patch electrode during a channel event and the
amount of elementary charge subsequently measured by the microamperometer.
By the data of this study, the authors favor the idea that the channel current is
coupled to transport, since each channel event measured under voltage clamp is
temporally correlated with the oxidation of “thousands of norepinephrine
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molecules.” Please see Figure I3. This result entails that a subset of the charges
moved during the channel event are the ones measured at the
microamperometry electrode. Thus it is justifiable to infer that the charges and
substrate travel via a common pathway (see also Petersen and De Felice 1999).

Figure I3: Channel-like events recorded during hNET
activity correlate in time with oxidation events
simultaneously recorded by a microamperometer held at
the oxidation potential for norepinephrine, +700mV.
Adapted from Galli, Blakely, and De Felice (1998),
Figure 4C.
It is conjectured that these findings may correlate with elegant
mechanisms of in vivo neuronal autoregulation. For example, relatively large,
fast, and voltage-dependent norepinephrine-gated hNET currents could
constitute a mechanism whereby the depolarizing uptake of norepinephrine
gradually reduces the driving force of subsequent uptake. It is noted that the
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concentration of neurochemical in the perisynaptic area can approach low
millimolar range, and that channel modes of hNET operation that couple the
translocation of substrate to powerful ion currents could be physiologically
beneficial. In fact, recording in vivo from the stereotypically serotonergic RetziusP cell synapse of the medicinal leech, Bruns et al. (1993) use caged Ca++—Ca++
liberated by light from an inactive storage conformation—to initiate a serotonergic
nerve impulse. This group measures the ensuing currents of both neurons of the
synapse, and finds that the current at the presynaptic Retzius cell initiates about
1ms after uncaging of Ca++, and well before the ionotropic response mediated by
serotonin has initiated in the post-synaptic cell. This current is certified as an
uptake current by monitoring simultaneous accumulation of an autofluorescent
serotonin analog, 5,7-dihydroxytryptamine. Please see Figure I4. This study
supports strongly the idea that monoamine transporter-induced currents drive
uptake of monoamines subsequent to a synaptic event.

Figure I4: uncaging of Ca++
via a flash of photons
(denoted by the arrow)
elicits a serotonergic
synaptic event.
Simultaneous recording
shows that the SERTmediated, presynaptic
uptake current initiates
before the post-synaptic,
serotonin-receptor induced
current. Adapted from
Bruns et al. (1993).
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Of high interest, Quick (2003) published work demonstrating that syntaxin
1A can abolish the channel-like current permeation events of hSERT, giving rise
to a functional transporter that lacks currents. In the syntaxin 1A-regulated state,
hSERT serotonin turnover rates parallel those measured in typical uptake
experiments, yet this process is accomplished in oocytes that reveal no currents
under two-electrode voltage clamp. Thus, a possible interpretation of these
results is that the variable-stoichiometry, channel-like mode of hSERT function
could be induced in vivo under certain physiological circumstances. In this
hypothesis, syntaxin 1A regulation functions to conserve the membrane potential
by switching the hSERT channel-like mode of function off when extracellular
concentrations of serotonin hover in the range that electroneutral transport can
manage. Or, syntaxin 1A may function to regulate the transport-associated
currents themselves, thus modulating the presynaptic feedback effects of
serotonergic spikes. Of note, Binda et al. (2008) found that sytaxin 1A overexpression in HEK cells potentiates amphetamine-induced, DAT-mediated
dopamine efflux.
Moreover, Ingram, Prasad, and Amara (2002) elegantly demonstrate the
plausibility that hDAT-mediated currents are physiologically relevant. Via wholecell current clamp recordings of cultured midbrain dopaminergic neurons of rat,
and controlling for D2, D1, and α1 metabotropic receptor-mediated membrane
potential modifications by means of blockade, this group demonstrates that
dopamine or amphetamine hikes the number of action potentials per unit of time.

20
This increase in excitability is blocked by cocaine, or by the selective DAT
inhibitor GBR12909. Correlating tritiated dopamine uptake to the magnitude of
recorded currents, it is found that, mirroring in vitro work, there exists a large
remainder when the current predicted by the stoichiometric model of transporter
function is subtracted from the magnitude of the recorded currents. Notably, the
group was unable to measure a leak current. Intriguingly, the group found that Clions carry at least a majority of the current permeation through rDAT, although a
discrepancy of 4mV exists between the reversal potential for the rDAT-mediated
current and the GABAA-mediated current, considered a pure Cl- current (-9mV
versus -5mV, respectively). This discrepancy may indicate that the current
possesses mixed ionic constituents.
Finally, the work of Carvelli et al. (2002) achieved total unity of the concept
that a channel mode is a natural component of the function of the monoamine
transporters by demonstrating that channel-like events occur during whole cell
recording of primary cultures of dopamine neurons of Caenorhabditis elegans,
whose dopamine transporter is termed DAT-1. These obvious channel events
“appear to be carried by Cl- ” and could be blocked by simultaneous
administration of the high affinity DAT-1 blocker imipramine. Neurons harvested
from C. elegans in which DAT-1 had been selectively knocked out did not
demonstrate channel events. Moreover, neurons harvested from C. elegans
engineered to over-express DAT-1 showed heightened channel activity. Taken
together, this work offers evidence that DAT-mediated currents may represent a
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respectable force within the dynamics of synaptic crosstalk, a force that could
magnify after the administration of exogenous drugs.
From the preceding paragraphs it is evident that the anatomy of
transporter-mediated currents is multifaceted. In addition to the manifestation of
channel-like events, which are observed by means of assays with fast time
resolution like patch clamping, there exist: a constitutive leak current, which is
resolvable both during patch-clamping and during two-electrode voltage clamping
(TEVC) of oocytes expressing transporter; a transient or peak current resolvable
during patch clamping and during TEVC with rapid superfusion capability; and a
persistent current, which is resolvable during patch-clamping and TEVC. The
leak current, which manifests as hyperpolarization of the baseline current upon
the administration of transporter inhibitors (please see Figure I5), is proposed to
consist of protons. The evidence for this claim comes from Sonders et al. (1997),
who observe that when the external concentration of protons is reduced by a
factor of 10, the reversal potential of hDAT for the cocaine-revealed leak
decreases by 38.5mV. In other words, the leak current is extinguished at more
negative values of the membrane potential when external pH is increased.

Figure I5: diagram of a portion of
the anatomy of a transporter
current, in this case that of
hNET recorded by patch
clamping. CO = control, DS =
desipramine-blockable. Adapted
from Galli, De Felice et al.,
1999, Figure 3C.
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The persistent current is an emerging object of study. In hDAT and dDAT,
it is induced in a time- and concentration-dependent manner by application of
(S)-amphetamine, and not by application of (R)-amphetamine. It is sodiumdependent, as NMDG+ substitution for sodium abolishes it. The working
hypothesis proposes that (S)-amphetamine modulates the transporter
conformation by interaction with an internal site, functioning as a “molecular
stent,” and activating an ion-flux mode of transporter function (De Felice et al.,
2011). Interestingly, the reversal potential for this current is obtained at a value of
about -20mV, and this value is consistent with the hypothesis that the persistent
current conducts chloride.
Future work by other groups has expanded upon the various mechanisms
of the electrogenicity of the monoamine transporters. Schicker et al. (2002) argue
from the stance that the excess current is uncoupled to substrate flux, a proposal
supported by the aforementioned fact that in hSERT, serotonin uptake does not
correlate with negative membrane potential (Mager et al. 1994). Schicker et al.
(2012) use a rapid solution exchange setup while recording from hSERTexpressing HEK cells to demonstrate that there exist two, functionally
disentangleable components of the serotonin-induced hSERT current. There is
an initial peak current, which decays less than 30% upon stepping from a
membrane potential of -100 to +20mV, and a steady state current of a slower
onset, which decays >60% across the same voltage range. Low intracellular K+
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abolishes the steady state current but not the peak current. To correlate current
with conformational states of hSERT, the group finds that 10µM serotonin and
Li+, both of which species induce current in hSERT-expressing oocytes, shifts
hSERT to an inward conformation as measured by NFRET and by increased
MTSEA labeling of a cysteine mutated into hSERT’s intracellular permeation
pathway. Uniting all observations into a model, it is proposed that transporters
initially translocate substrate by means of a fixed stoichiometric transport cycle.
This process gives rise to the transient current. In turn, this process shifts the
conformation of hSERT inward; then internal K+ gates the current conduction of
this state of the transporter, and the steady state current emerges from this
process. However, given: serotonin induces an inward-facing state of the
transporter, and serotonin induces current, it is not clear that we are forced to
conclude that serotonin induces current by means of inducing an inward-facing
state of the transporter.
In conclusion, it seems to be the case that a high degree of conceptual
and functional spillover exists between transporters and channels. As a
remarkable illustration, a minor degree of genetic divergence of the genes for the
sodium-glucose transporter SGLT-3 between swine and human has engendered
a radical divergence of function. In swine, SGLT-3 transports glucose, and in
humans, it is a glucose-gated Na+ channel, and functions to sense the
extracellular concentration of glucose (Diez-Sampedro et al., 2003). It is also
interesting to ponder the evolutionary forces that have given rise to human
versions of the dopamine and serotonin transporters which permeate currents
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that are attenuated by a factor of 4 or so relative to their counterparts of
Drosophila melanogaster.
2. Pharmacology
The field of monoamine transporter biophysics and pharmacology has
been systematized by means of two paradigmatic concepts: those of the
monoamine transporter substrate and the monoamine transporter inhibitor. A
substrate is conceptualized as a molecular species that translocates through the
transporter into the intracellular space, much like the transporter’s endogenous
substrate. Additionally, a traditional monoamine substrate effects efflux of the
transporter’s endogenous substrate into the perisynaptic space, and is also
termed a releaser. An inhibitor binds the transporter and obstructs the native
function of the transporter; in the imagery of the model of alternating access,
inhibitors bind to and stabilize the outward facing conformation of the transporter,
a prediction borne out by recent structures of dDAT and hSERT co-crystalized
with bound inhibitor (Wang et al., 2015; Coleman, Green, and Gouaux, 2016).
Consequently, the obstructed transporter is partly compromised in its function,
and monoamines accumulate in the perisynaptic space. The assignment of drugs
to one of these classes is accomplished via experiments measuring uptake or
release, and via electrophysiological assays, in which substrates induce current,
while inhibitors manifest by blocking the leak currents inherent to transporters.
Within these categories, in addition to the traditional substrates, which are
like amphetamine, and traditional inhibitors, which are like cocaine, there are
compounds whose pharmacological profile at their target transporter is more
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nuanced. For example, atypical inhibitors like the nootropic modafinil and the
antidepressant and smoking cessation drug bupropion function to stabilize an
inward-facing conformation of the dopamine transporter (Schmitt et al., 2013;
Schmitt and Reith 2011). Interestingly, this mechanistic distinction from the action
of cocaine-like inhibitors may underlie the low abuse liability associated with
modafinil and bupropion compared to cocaine.
Complicating matters, a class of quinazolimine compounds exerts an
effect at hDAT that is functionally distinct from that of a substrate or inhibitor.
These compounds have been characterized as allosteric modulators, and
interact with a site separated in space from the substrate binding site. Strikingly,
a certain molecule, SoRI-20041, inhibits the uptake of tritiated dopamine in a
striatal synaptosome assay, yet lacks the expected inhibitory effect on (S)amphetamine-induced release of tritiated dopamine (Rothman et al., 2009). The
results of this study demonstrate that substrate uptake and substrate-induced
substrate release “can be separately modulated” (Rothman et al., 2009). Finally,
it is notable that cocaine may function as a partial releaser. In mice, electrical
stimulation at the medial forebrain bundle gives rise to dopamine release in the
caudate-putamen. In wild-type mice, the amount of dopamine measured 10
minutes after cocaine introduction is increased by about 150% compared to the
value measured under control conditions. However, in synapsin I/II/III triple
knockout mice, the stimulation-induced dopamine release is measured at only
74% of the control value (Venton et al., 2006). The authors propose, therefore,
that without synapsins, cocaine is unable to “mobilize dopaminergic vesicles”
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from a vesicular reserve pool, and that this downstream effect may contribute to
cocaine’s total dopaminergic profile in vivo.
Furthermore, a vein of SERT pharmacology argues for the functional
relevance of the S2, or allosteric, site, situated superior to the substrate binding
site, within the extracellular vestibule. It is proposed that the allosteric site
functions as a site of allosteric modulation of transporter function and is a target
of drugs used in the treatment of major depressive disorder. In support, the
hSERT crystal structure of Coleman, Green, and Gouaux (2016) features two
bound (S)-citalopram molecules in positions consistent with the central binding
site and the allosteric site of the extracellular vestibule. It is noted that
experimentally, (S)-citalopram within the bath solution retards the rate of tritiated
citalopram dissociation from the central binding site compared to the rate
observed without (S)-citalopram, leading to the inference that drugging of the
allosteric site can modulate the binding of pharmaceuticals to the central binding
site.
Amphetamine (AMPH) (1-phenylpropan-2-amine) and its analogs are
sympathomimetic compounds that give rise to psychoactive effects by means of
indirect dopamine, norepinephrine, and serotonin receptor agonism resulting
from their action as monoamine releasers. Secondly, amphetamine functions as
a reversible inhibitor of monoamine oxidase A, an enzyme that functions in
tandem with the monoamine transporters to terminate the presence of
monoamines (Ramsay and Hunter, 2003). Thirdly, amphetamine acts as a
competitive inhibitor of monoamine transporter uptake of endogenous
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monoamine substrate; one study measured that, recording from caudateputamen slices, the apparent affinity of dopamine uptake fell from .8µM to 32µM
after 20 minutes of 10µM (S)-amphetamine superfusion (Schmitz et al., 2001).
Finally, amphetamine gives rise to the endocytosis from the membrane of a
portion of the DAT population (Kahlig et al., 2004).
A prevailing model of the pharmacodynamics of amphetamine and
amphetamine analogs (hereafter referred to as the amphetamines) attributes
their propensity to cause monoamine release to their capacity to force the
monoamine transporters to run in a reverse mode. In this mode of reverse
transport, the transporters move substrate from the neuronal cytoplasm, pumping
it into the extracellular space. An initial mechanistic framework for reverse
transport is the facilitated exchange diffusion model. Incorporating the concepts
of the model of alternating access, this model proposes that exogenous
substrates shift the equilibrium of the transport cycle to favor an inward-facing
conformational state; thus, the transporter is much more likely to bind intracellular
dopamine and translocate it to the extracellular space on its return to the outward
facing position. In this model, the excess import of the exogenous substrate also
imports more sodium, which pushes the inward facing, dopamine-bound
transporter back to its outward facing position.
However, this model of facilitated exchange diffusion is too simplified to
account for a host of experimental results, and a subtler model, in which the
reverse-acting transporters retain the complexities inherent to the forward mode
of operation, is more favorable. For example, ouabain, as a result of
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Na+/K+ATPase inhibition and increased intracellular Na+ concentration, facilitates
the efflux of substrate, implying that exogenous substrate permeation through the
transporter is not necessary to initiate reverse transport, and the flux of sodium is
a catalyst for the switch in transport mode (Sitte and Freissmuth, 2010). As an
additional example, injection of amphetamine directly into the cytoplasm of the
giant dopamine neuron of Planorbis corneus gives rise to nomifensine-blockable
release of dopamine, again leading to the conclusion that exogenous substrate
transport is not necessary for exogenous substrate-induced reverse transport
(Sulzer et al., 2005). In addition, recording from outside-out patches of hDATexpressing HEK cells, Kahlig et al. (2004) find that, with the membrane potential
clamped to +20mV, 10µM amphetamine application induces rapid, channel like
events. Implementing simultaneous microamperometry, two distinct modes of
dopamine efflux are discernable. There is a slow flow of dopamine, consistent
with “transporter like behavior,” measurable as both current and oxidation. This
transporter-like behavior manifests as a current with slow activation, and as a low
magnitude oxidation current. Upon expansion of the time scale of the current
traces and low-pass filtering of the microamperometry traces, there are revealed
distinct, transient spikes consistent with intermittent channel-like behavior. The
microamperometric events “correspond to large amounts of DA rapidly crossing
the plasma membrane and being oxidized.” The greater potency of
amphetamine, compared to dopamine, to induce reverse transport is attributable
to amphetamine’s mediation of an uncoupled current of greater magnitude (Sitte
et al., 1998). If the uncoupled current flux associated with amphetamine were
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equal to that of dopamine, it would be difficult to cognize how futile cycling, in
which dopamine transport via hDAT is haphazardly bi-directional, would not
obtain in vivo. Finally, it is noteworthy that amphetamine has been shown to
upregulate the activity of protein kinase C, which phosphorylates DAT and may
stimulate it to function in the reverse mode (Giambalvo, 2004).
In addition to its action on the plasmalemmal monoamine transporters,
having breached the cell, amphetamine targets the vesicular monoamine
transporters (VMATs), especially VMAT2. In fact, amphetamine has an apparent
affinity for VMAT2 (2µM) within the range of that of dopamine itself (1.4µM), as
measured by Erickson et al. 1996. VMAT2 concentrates molecules of biogenic
monoamine into vesicles by means of antiportation of 2 protons for each
molecule of monoamine. The action of Na+/H+ ATPase establishes this proton
gradient, which can be harnessed to establish a vesicular concentration of
monoamines of up to 1M (Sulzer et al., 2002). Pre-treatment with reserpine, an
irreversible inhibitor of VMAT2, gives rise to the blockade of norepinephrine
release, as measured by in vivo microdialysis, at all doses (.5, 1.25, and
5.0mg/kg) tested by Florin, Kuczenski, and Segal (1995). This group also
measured significant attenuation of dopamine release within the caudateputamen at the doses of .5mg/kg and 5.0mg/kg, yet measured no change at the
intermediate dose. This discrepancy is likely attributable to reserpine’s curious
action as a booster of tyrosine hydroxylase activity, an action that raises the
cytosolic concentration of dopamine (Sulzer et al. 2005). Indeed, upon a reduced
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reserpine exposure time of 90 minutes, cultured midbrain dopaminergic neurons
released 75% less dopamine upon amphetamine exposure.
Amphetamine functions as a substrate of VMAT2 (Freyberg et al. 2016;
Partilla et al. 2006), infiltrates monoaminergic vesicles, and gives rise to
redistribution of the concentrated vesicular monoamines into the cytoplasm. This
surge in cytoplasmic monoamine concentration marks the inception of reverse
transport by the plasmalemmal monoamine transporters. The mechanism
whereby amphetamine permeation of monoamine vesicles via VMAT2 causes
cytosolic redistribution of vesicular stores plausibly may occur by two, nonexclusive schemes. In the first, the artificially elevated concentration of VMAT2
substrate penetrates the vesicular environment more quickly than the vesicular
Na+/H+ ATPase can compensate to maintain the magnitude of proton gradient
necessary for the astronomical concentration of substrate. Consequently, a
population of the monoamines within vesicular storage escapes via VMAT2 into
the cytoplasm. In the second mechanism, amphetamine, itself a weak base,
compromises the vesicular proton gradient by means of the buffering of
intravesicular protons by neutral species of amphetamine. However, the ratio of
physiologically charged : uncharged amphetamine has been estimated at only
300 : 1 (Freyberg et al., 2016). Thus, the principal mechanism of amphetamineinduced redistribution of vesicular monoamines is most plausibly attributable to
its mass action as a VMAT2 substrate.
Having caused the presynaptic efflux of monoamines by means of the
preceding detailed scheme, what mechanisms initiate the downstream results of
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amphetamine administration? The amphetamine-induced rise in extracellular
dopamine heightens D2 receptor signaling throughput. D2 receptor activity
transduces dopamine binding to the activation of outwardly rectifying potassium
channels, hyperpolarizing the dopaminergic neuron and attenuating stimulusdependent, exocytotic dopamine release (Schmitz et al. 2001). However,
Paladini et al. (2001) challenge the notion that dopamine always attenuates
bursting via a D2 receptor-mediated mechanism; rather, they propose that
dopamine neuronal bursting may be facilitated by amphetamine’s indirect action
at α1 adrenergic receptors at the postsynaptic area of glutamate to dopamine
synapses. Recording from midbrain slices, this group finds that 10µM
amphetamine administration reduces the amplitude of α1 adrenergic receptormediated inhibitory post-synaptic potentials, yet does not affect ionotropic
glutamate receptor-mediated excitatory post-synaptic potentials. Thus in vivo, by
this mechanism amphetamine could increase the probability of dopaminergic
bursting, owing to enhanced signal strength of ionotropic throughput. Additionally,
amphetamine-induced dopamine release gives rise to D1 receptor-mediated
upregulation of glutamate release from glutamatergic neurons of the ventral
tegmental area (Licata and Pierce, 2004).
In vivo microdialysis recording from the hippocampus of rats has
demonstrated that amphetamine administration at doses of 1mg/kg and 2mg/kg
effects an increase in concentrations of acetylcholine over basal values of 110%
and 210%, respectively (Imperato, Obinu, Gessa, 1993). Inhibition of the D1
receptor antagonizes this surge of acetylcholine. Additionally, amphetamine is an
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agonist at the GαS-coupled, intracellular trace amine associated receptor 1
(TAAR1). Interestingly, this receptor has been shown to co-localize with DAT in
rhesus monkey neurons of the substantia nigra (Miller, 2011). Thus, DAT may
feed amphetamine into areas of TAAR1 expression, inducing local spikes in
cAMP synthesis, which activate PKC. In this scheme, PKC phosphorylates DAT.
This PKC-mediated post-translational modification has been correlated with
amphetamine-induced dopamine efflux via DAT (Robertson, Matthies, and Galli,
2009). Finally, in light of the robust knowledge of transporter-associated currents,
it is conceivable that amphetamine exerts more upstream effects on
dopaminergic neurons via the monoamine transporters themselves.
The spectrum of the amphetamines’ total pharmacodynamics is wide.
Modification of the amphetamine skeleton can take a stimulant
(methamphetamine) to a psychedelic (DOM, 2,5-dimethoxy-4-methylamphetamine) to an entactogen (MDMA, 3,4-methylenedioxy-methamphetamine)
to a neurotoxin (4-chloro-amphetamine). The modification of amphetamine’s ring
and alkyl chain modulates the resulting compound’s relative affinities for the
transporters of dopamine, serotonin, and norepinephrine and, in the case of
DOM, adds the dimension of 5HT2A/2C receptor agonism to its pharmacological
profile. The total profile of the amphetamines’ transporter and receptor affinities
shapes their behavioral correlates. Remarkably, while (+)-pseudophenmetrazine
functions as a dopamine transporter substrate, (-)-pseudophenmetrazine
functions as a dopamine transporter inhibitor (Partilla et al., 2001). Thus it is
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evident that minor structural alterations can give rise to radically divergent
pharmacodynamics.
The inversion of the stereocenter--typically there is just one stereocenter-of the amphetamines can give rise to two compounds with markedly different
pharmacodynamics. In fact, the (R) enantiomer of methamphetamine, labeled by
the hidden-in-plain-sight moniker “levmethamfetamine,” until quite recently was
sold as an over-the-counter nasal decongestant. Meanwhile, (S)- and racemic
methamphetamine are potently addictive and psychotomimetic drugs of abuse,
and have catalyzed a national public health scourge within the United States.
Data from synaptosome and in vivo microdialysis experiments clarify the
pharmacodynamic basis of the distinct physiological effects mediated by each
enantiomer. Crucially, the (R) enantiomer of amphetamine is more heavily
weighted toward action on norepinephrine systems than dopamine systems.
Measuring the propensity of each enantiomer of amphetamine to block the
reuptake of tritiated monoamines into synaptosomes, two independent studies
report that (R)-amphetamine displays a 4-5 fold greater potency to block
norepinephrine uptake compared to its potency to block dopamine uptake
(Richelson and Pfenning, 1984; Easton et al., 2007). Further, Cheetam et al.
(2007) found 1.0mg/kg (R)-amphetamine gave rise to 407+/-56% of basal
norepinephrine efflux in the prefrontal cortex, while at the same concentration the
corresponding value for (S)-amphetamine was 429+/-133%. In contrast, at a
concentration of 3.0mg/kg, (S)-amphetamine gave rise to 4898+/-1912% of the
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baseline dopamine efflux in the striatum, while the corresponding value for (R)amphetamine was just 644+/- 208%.
3. Medical Science
3.1 Traumatic brain injury
Traumatic brain injury (TBI) has been marked a “silent epidemic” within
the United States, with the Centers for Disease Control and Prevention
estimating that 1.7 million persons within the United States suffer a TBI each
year; meanwhile, 3.2-5.3 million persons live with disabling sequelae from TBI.
Data on economic burden is hard to come by, doubtlessly due to the
heterogeneity of injuries rightly classified as a TBI; however, one study pegs the
2001-2005 cost due to lost productivity resulting from TBI in Missouri at $1.1
billion. Within the Netherlands, TBI accounts for 171,200 disability adjusted life
years (DALYs), a metric which quantifies the years of healthy life lost due to a
particular disease, representing an average of 7.1 DALYs per case (Scholten et
al., 2014). Considering these numbers, it is clear that medical science must
develop new methods of treatment to mitigate the substantial consequences of
this debilitating and personal type of injury.
Following the primary TBI, which encompasses the mechanical force and
resulting trauma which the foreign body has exerted on the cranium, there
follows a secondary injury stage, which results from downstream biochemical
effects which the primary cellular injuries initiate. Vascular hypotension and
resulting hypoxemia give rise to compromised neuronal ATPase activity, ruining
the neuronal membrane potential and giving rise to depolarization. This
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pathological depolarization gives rise to the release of glutamate from
intracellular stores. Accumulating glutamate in turn triggers the NMDA-sensitive
glutamate-gated ion channels, which permeate calcium haphazardly. The result
is excitotoxicity and further neuronal damage.
Currently, there are no approved pharmaceutical interventions for either
stage of traumatic brain injury, and the field has been exceedingly busy
conducting trials of candidates within various drug classes. The field is currently
focused on the glycine site-NMDA partial agonist cycloserine and has been more
focused on the NMDA receptor in general (Shohami and Biegon, 2014);
however, another current with TBI pharmaceutical research has concentrated its
effort on intervening within the dopamine system by means of the
neuroprotective effects of low-dose methamphetamine. Rau et al. (2012, 2014)
demonstrate that the administration of low-dose (<1.0mg/kg) methamphetamine
to rats 8 hours after a TBI yields increased CA1 hippocampal neuronal survival
compared to saline and compared to methamphetamine administration at 12
hours post TBI. Low-methamphetamine-treated rats displayed a statistically
significant improvement in the survival of hippocampal hilar region mossy cells
compared to untreated control. TBI-injured rats treated with low-dose
methamphetamine also performed better on cognitive tests of learning and
memory (the Morris water maze test) compared to untreated injured rats. Like so
many aspects of the pharmacological profile of amphetamine, methamphetamine
could mediate an inverted U-shaped scheme of neuroprotective effects, in which
low doses are neuroprotective until higher doses become neurotoxic.
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3.2 Orthostatic intolerance
There is a bona fide transporteropathy associated with mutations of the
gene for the human norepinephrine transporter (hNET): orthostatic intolerance.
This pathology is characterized by syncope, fatigue, and lightheadedness
brought about by the assumption of an upright posture from a supine position.
The heart rate also rises by at least 30 beats per minute after this postural
transition. A pivotal case study, Shannon et al. (2000), measured indexes of
norepinephrinergic metabolism from a 33-year-old woman with a 20-year history
of the symptoms of orthostatic intolerance. Physiological testing revealed that
she had markedly higher than average heart rate while standing, along with
dramatically elevated concentrations of plasma norepinephrine (923 v. 439
picograms/milliliter). Her rate of plasma norepinephrine clearance was also
slowed compared to that of healthy controls. Sequencing the region of her
genome harboring the sequence for hNET, it was discovered a single missense
mutation Ala457Pro, residing in transmembrane domain 9, a region of high
conservation of cross-species norepinephrine transporters. Having synthesized a
construct in which the Ala457Pro point mutation was spliced into wild-type hNET,
it was found that this construct cleared tritiated norepinephrine in vitro at about
2% of the efficacy of the wild-type transporter. Although the authors note that
other patients with orthostatic intolerance lack this specific mutation, this case
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study proves that transporters intricately tune the neurochemical environment in
response to external forces.

3.3 Attention deficit hyperactivity disorder
Attention deficit hyperactivity disorder (ADHD) is a complex behavioral
and cognitive dispositional disorder specified by the DSM-5 according to clusters
of interrelated symptoms that may co-occur. ADHD is subclassified into its three
most common distinct clinical presentations: inattentive; hyperactive/impulsive;
and combined, which marks a presentation encompassing all three properties.
Classified as a neurodevelopmental disorder, symptoms must be present before
the age of 12. Estimates of the prevalence of ADHD vary widely depending on
the epidemiological methodology of a particular study; however, a typical global
prevalence range falls between 5% (Polanczyk et al. 2007) and 7% (Wilcut et al.
2012) for children and adolescents. In the United States in 2005, physicians
wrote 16 million prescriptions (Gross 2005) for the frontline pharmaceuticals used
clinically to ameliorate the symptoms of ADHD: methylphenidate and
amphetamine.
Conceptually present in medical literature since the late 1780s, in 1937 a
Rhode Island physician made a chance pharmacological finding that spurred the
study of the pathophysiology of ADHD, and the study of attention in general. Dr.
Charles Bradley was a neurologist treating children with organic neurological
disorders and children hospitalized due to emotional and behavioral problems.
Attempting to allay the headaches resulting from an outdated medical technique
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known as a pneumoencephaologram, Dr. Bradley noted that the administration of
racemic amphetamine gave rise to tranquilized behavior and improved academic
performance in some children. With the synthesis of methylphenidate in 1944,
clinicians started to prescribe stimulant medications to hyperkinetic children at an
expanding rate (Lange et al. 2010).
Concurrently, pioneering studies in neurochemistry and neurophysiology
began to bear out the correlations between monoaminergic systems and
cognition. For example, the concept emerged of dopamine’s importance in the
inhibitory control and direction of motor output, in working memory, and in the
modulation of an organism’s conditioned reinforcement while behaving, along
with the association of stimuli with reward value in general (Solanto 1998;
Solanto 2001). An interesting hypothesis characterizes the human with ADHD as
possessing an elevated threshold for the experience of rewarding effects from
stimuli. Thus, it is further hypothesized that psychomotor stimulants, via
alterations of striatal dopamine signaling, empower the control that conditioned
stimuli exert over behavior. In other words, the child with ADHD may be able to
perceive the correlation of a reward and its source subsequent to the completion
of some task, like execution of schoolwork, which had been missed during
baseline cognition. Reinforced, the child is more likely to re-engage the
conditioned stimulus (e.g. the textbook). Additionally, heightened dopaminergic
tone within the prefrontal cortex (PFC) has been demonstrated to dampen the
sensitivity of these neurons to respond to novel stimuli (Thierry et al., 1992); this
type of effect may aid in the attenuation of the components of inattentiveness
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characterizing ADHD. It is well-established that therapeutic doses of
psychostimulants enhance cognition—working memory and response inhibition
in particular—in the general population (Spenser et al., 2015). These therapeutic
effects arise in large part owing to the psychostimulants’ actions as indirect D1,
D2, and α2 receptor agonists within the PFC (Spenser et al., 2015).
Finally, the neuropharmacology of norepinephrine is within the same tier
of importance as dopamine within the pathophysiology of ADHD. It has been
shown that α2 adrenergic input within the prefrontal cortex is a principal mediator
of visual attention (Glaser and Gerhardt 2015). In general,
norepinephrinergic projections modulate the processes of stimulus selection and
sensory gating, expectation (Yu and Dyan 2005), and the maintenance of
attention. Locus coeruleus innervation of the prefrontal cortex and basal forebrain
is a principal system controlling the state of an organism’s arousal, and
norepinephrinergic tone of the locus coeruleus obeys the Yerkes-Dodson law,
wherein a plot of arousal versus performance takes the shape of an inverted U.
In other words, both too-low and too-high levels of norepinephrinergic input
aberrantly affect performance on tasks requiring optimal levels of arousal, which
is maintained at moderate levels of locus coeruleus output. Consequently,
amphetamine’s action as a norepinephrine releaser is bound to contribute to its
efficacy in the treatment of ADHD. In fact, atomoxetine, a norepinephrine
transporter inhibitor, shows efficacy in the treatment of ADHD; however, like
amphetamine, its effects are due in part to heightened extracellular levels of
dopamine as well, since the NET is responsible for a large portion of dopamine
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reuptake in the prefrontal cortex (Moran et al. 2002). The specific cellular and
connectomic mechanisms involved in stimulant medication’s amelioration of the
attention deficits of ADHD remain to be characterized robustly.
Further, an interesting vein within ADHD research concerns the intricate
dependence of the pharmacodynamic profile of amphetamine on the
concentration of the dose administered. For example, the locomotor facilitation of
(S)-amphetamine is also described by an inverted U-shaped curve, in which
lower doses (~ .5mg/kg) facilitate locomotion linearly with increasing dose until
stereotypy, or the repetition of pointless behavior, begins to dominate, and the
rats grow more still. Furthermore, it is proposed that at clinically therapeutic
dosing regimens, the primary mechanism of amphetamine is to attenuate a
pathological rhythm of phasic spiking by dopamine and norepinephrine neurons
by means of raising the tonic synaptic concentration of dopamine and
norepinephrine, which in turn quiets aberrant spiking by means of D2 and α2
autoreceptor feedback (Seeman and Madras 1998). Devilbiss and Berridge
(2006) describe evidence that a similar mechanism is implicated within the
norepinephrine system. This group found that at low, clinically relevant dosages,
methylphenidate suppressed both tonic and phasic discharge of locus coeruleus
projections, the result possibly being the narrowing of the attentional spotlight to
exclude non-salient distractors (Aston-Jones et al., 1999).
Extrapolating to humans, the question becomes whether monoaminergic
inhibitory or facilitative effects represent the most crucial aspect of the
therapeutic profile of amphetamines. Stating the puzzle in different terms, are the
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presynaptic feedback effects or postsynaptic feedforward effects more important
mediators of clinical amphetamine’s effects? Are hyperactive norepinephrine and
dopamine systems constrained toward less bifurcatory behavior, or do stimulant
drugs exert beneficial calming effects commensurate with the propensity to
induce stereotypy and its associated decrease in locomotor activity? Solanto et
al. (1986) offers evidence in support of the autoreceptor hypothesis: this group
found that even quite low, subclinical dosages of methylphenidate (.1mg/kg)
reduced levels of activity in children with ADHD. Rapport et al. (1980) found that
doses of .25mg/kg (S)-amphetamine also gave rise to the same reduction in
locomotion when administered to boys aged 6-12, both with and without the
diagnosis of ADHD. Since these dosages are far outside of the range of inducing
stereotypy in mice (McNamara et al., 2003), it may be inferred that the drug
reduces activity by means of autoreceptor-mediated adjustments of
dopaminergic tone. Rejecting a dichotomy, therapeutic amphetamine may
orchestrate a complex mixture of pre- and postsynaptic effects throughout
various regions of neuroanatomy.

3.4 Parkinson’s disease
Parkinson’s disease (PD) is a neurodegenerative disease that gives rise to
pathology of motor system output—including rigidity, bradykinesia, and tremor—
owing to the death of dopaminergic efferents from the substantia nigra, pars
compacta. Neurons of the substantia nigra, pars compacta express
concentrations of hDAT higher than neurons of the ventral tegmental area or the
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tuberoinfundibular pathway (Storch, Ludolph, Schwarz, 2004). Polymorphisms
within regions of variable number of tandem repeats (VNTR) at the 3’
untranslated region of the hDAT gene have been correlated with idiopathic PD.
This association has led to the hypothesis that patients acquiring idiopathic PD
may harbor dopamine transporters that accumulate environmental toxins with a
greater affinity (Le Couteur et al., 2004). Concentration of striatal hDAT can
decrease 30-50% during the early stages of the disorder. Nuclear medicine
physicians use radiolabeled ioflupane, a high-affinity hDAT blocker, in
conjunction with single photon emission computed tomography (SPECT) to
assess the progression of dopaminergic neuronal degeneration. The principal
medicinal therapeutic for this disease is oral L-DOPA, a precursor of dopamine
that can cross the blood-brain barrier, and, interestingly, concomitant
administration of the hDAT inhibitor methylphenidate has been shown to
potentiate the response effects of threshold doses of L-DOPA (Nutt et al., 2004).
A major current within PD research proposes that reactive oxygen species
deriving from the hydroxyls of dopamine give rise to gradual neurotoxic effects
within dopaminergic neurons. Therefore, regulation of hDAT is naturally
implicated as a plausible component within the pathogenesis of PD, since
substantial up-regulation of hDAT could cause higher intraneuronal
concentrations of dopamine. α-synuclein is a chaperone-like protein species
involved in the tuning of dopamine biosynthesis by means of suppression of
tyrosine hydroxylase, the rate-limiting enzyme of dopamine biosynthesis.
Additionally, α-synuclein modulates hDAT, binding at its C-terminal tail.
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Unfortunately, there has arisen no consensus concerning the functional
consequences of this inter-proteomic interaction. Moszczynska et al. (2007)
report that α-synuclein complexes with hDAT, clusters it together, and
accelerates hDAT’s uptake of dopamine, while Swant et al. (2011), working in
immortalized dopamine neurons, directly contradict this finding. Further, Swant et
al. (2011) find that α-synuclein over-expression gives rise to increased hDATmediated inward current, which is blocked by the selective hDAT antagonist
GBR12935. Most interestingly, Swant et al. (2011) find that α-synuclein overexpression under conditions in which the external Cl- gradient is decreased by
isosmotic substitution of NaCl for Na acetate gives rise to an additional increase
in inward current, above the condition of elevated α-synuclein under control
concentrations of external Cl-. Thus, future research must clarify the functional
interdependence of α-synuclein’s modulation of hDAT-mediated conductance
and oxidative stress within the pathophysiology of PD.

4. Voltage-gated Ca++ channels and Ca++ homeostasis
The L-type family of voltage-gated calcium channels, also known as the
dihydropyridine receptors, are ion channels that transduce a depolarizing change
in the membrane potential of cells, importantly of myocytes and neurons, into
intracellular calcium flux. The central pore-forming unit is termed α1, and is a
monomeric construct consisting of 4 subunits, which themselves consist of 6
transmembrane helical regions dubbed S1-S6, with S4 being the region of
voltage sensation. The α2, δ, and γ auxiliary subunits regulate membrane
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expression of the pore-forming subunit, modulate voltage sensitivity and gating
properties, and control drug binding interactions at the pore-forming subunit
(Triggle, 2006). Physiologically, the L-type calcium channels, which contain the
members CaV1.1, CaV1.2, CaV1.3, CaV1.4, are classified as high-voltage
activated channels, and comprise the mechanistic basis for excitation-contraction
coupling within myocytes. They further mediate excitation-transcription coupling
within myocytes, gate forms of synaptic plasticity (Frank, 2014), and regulate
secretion of neurochemicals and hormones (Lipscombe et al., 2004). The L of Ltype refers to the fact that activation of these channels is long-lasting; in other
words, they are slowly inactivating after activation.
The channels presently under study are CaV1.2 and CaV1.3, which are the
dominant isoforms of L-type calcium channels within the brain (Hirtz et al., 2001).
Importantly, Cav1.2, in conjunction with the ryanodine receptor, is a mechanistic
component of excitation-contraction coupling within myocytes, and Cav1.3 is
crucial for proper auditory perception (Brandt et al., 2003). Although both species
of calcium channel are classified as high-voltage activated, there is a marked
difference in the activation threshold between these two isoforms, with Cav1.3
activating at more hyperpolarized membrane potentials. Please see Figure I6.

Figure I6: peak current
versus voltage for Cav1.2
(blue; open circles) and
Cav1.3 (red; closed circles),
recorded from oocytes in
5mM Ca++ external solution.
Modified from Xu and
Lipscombe (2001), Figure
1D.
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As Figure I6 demonstrates, Cav1.3 activates at a membrane potential about
25mV more hyperpolarized than the threshold potential of Cav1.2, consistent with
a role of Cav1.3 in neuronal processes driven by spontaneous pacemakers (Xu
and Lipscombe, 2001).
In general, the intracellular concentration of Ca++ is maintained by means
of homeostatic mechanisms at a concentration of about 100nM (Triggle, 2006),
while extracellular concentrations are about 1mM, representing a Ca++ gradient
of about 10,000 held across the plasma membrane. Excessive intracellular Ca++
is toxic; in addition, Ca++ is a potent second messenger whose signal to noise
ratio must be sustained (Simmons, 1988). A series of membrane-bound pumps
and exchangers functions to maintain this impressive Ca++ gradient. A portion of
the pumps that participate in intracellular Ca++ homeostasis resides on the
plasmalemma, and a portion resides on the endoplasmic reticulum, from which
large stores of Ca++ may also be released. The plasma membrane Ca++ ATPase
(PMCA) functions in tandem with the Na+/Ca++ exchanger (NCX) at the plasma
membrane in order to monitor and clear intracellular Ca++ ions. The NCX is
characterized as low-affinity, high-capacity; in other words, it can expel large
amounts of Ca++ from the cell while the intracellular Ca++ concentration is high,
and thus is widely expressed in excitable cells like neurons and myocytes (Brini
and Carafoli, 2001). The PMCA is characterized as high-affinity, low-capacity,
and functions to expel the Ca++ that, for example, enters the cell during signaling
events less dramatic than an action potential. Ca++ is also sequestered into the
endoplasmic reticulum by way of the sarco-/endoplasmic reticulum Ca++ ATPase,
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and Ca++ binding proteins like calmodulin further bind and buffer intracellular
Ca++.

5. Compounds under study
The compounds under study in this work are the enantiomers of N-methyl1-(4-methylphenyl)propan-2-amine and N-ethyl-1-(4-methylphenyl)propan-2amine, abbreviated within the body of this text to N-Me 4-Me AMPH and N-Et 4Me AMPH, respectively. They are enantiomers of the N-alkylated analogs of 4Me AMPH. Please see Figure I7.

Figure I7: N-alkyl analogs of 4-methyl amphetamine (AMPH) under study.
Calcium fluorescence dose v. response data derived from compounds
retain color-coding.
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4-methyl AMPH is the subject of an interesting study by Bauman et al. (2011).
This study found that the addition to amphetamine of the methyl at the 4-position
markedly boosts the in vitro potency of 4-methyl AMPH as a releaser of serotonin
from synaptosomes preloaded with tritiated serotonin. Simple (S) amphetamine
yielded a potency ratio for dopamine release : serotonin release of 219; 4methylation shifted this ratio toward serotonin dramatically--to 1.2. In the in vitro
synaptosome studies, 4-methyl AMPH was compared to (S)-AMPH and to three
additional ring-substituted AMPH analogs: 3- and 4-fluro AMPH and 3-methyl
AMPH. All 4 ring-substituted AMPH analogs yielded similar values of potency as
dopamine releasers, and 4-methyl AMPH yielded the most potent value as a
serotonin releaser. Each ring-substituted compound was about equally potent as
a norepinephrine releaser, with potency on the order of 20nM.
The shift in the pharmacodynamic profile of the drug toward greater
potency as a serotonin releaser was mirrored during in vivo microdialysis studies
from the nucleus accumbens in freely moving rats. At doses of 1mg/kg, 4-methyl
AMPH gave rise to serotonin release above baseline significantly different than
the three other ring-substituted amphetamines. Interestingly, at 3.0mg.kg, 4-Me
AMPH was the weakest dopamine releaser, although nonetheless elevated
dopamine to levels significantly higher than control. Thus the group concluded
that in vivo, a negative correlation exists between potency as a dopamine
releaser and potency as a serotonin releaser. Expanding, the group found a
significant positive correlation between locomotion and the ratio of the % rise
from basal levels of dopamine compared to serotonin. Therefore, the emerging
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concept from this study is that drugs with a higher propensity for serotonin
release dampen dopamine release and ambulation.
The measurements derived from the work of Bauman (2011) agree with
the reports offered by a fringe subset of Homo sapiens, who describe the
subjective effects of 4-Me AMPH as possessing entactogenic and stimulant
qualities (Blanckaert, 2012). Subjective experience of entactogenic qualities, in
which tactile perceptions are magnified in detail and emotional valence, is
correlated with serotonin releasers, most famously MDMA, or ecstasy. Also in
agreement with the work of Bauman (2011), Higgs and Glennon (1990) found
that 4-Me AMPH only partially substituted for (S)-AMPH in rats trained to
differentiate 1mg/kg (S)-AMPH from saline. 4-Me AMPH gave rise to a factor of
.5 less response from rats compared to the response elicited by (S) AMPH.
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II. Materials, Methods, and Data Analysis
1. Epifluorescence calcium imaging microscopy
In order to assay the compounds under study at hDAT and hNET,
permanent cell lines, having been previously established, are thawed from liquid
nitrogen storage as needed for experimentation and maintained in DMEM
augmented with 1% penicillin and streptomycin, along with 10% Hyclone fetal
bovine serum, for up to about 12 passages at 37 degrees Celsius under standard
mammalian cell conditions. Three to four days prior to an experiment, cells are
plated on 96-well plates coated with 35µl Matrigel (Corning) at 30-60%
confluency. For hNET, it is crucial to plate at the lowest portion of this range in
order to measure calcium signals from a steady baseline. For plating with hDAT,
the measurement of very clean calcium signals seems less correlated with initial
plating confluency. Cells are maintained for at least 2 hours to allow cells to
attach to the imaging plates. Cells are transfected using FuGENE 6 reagent
(Promega) in an antibiotic free transfection mixture. For hDAT, per 24 wells, the
transfection protocol uses 1µg of the CaV1.2 alpha subunit, which has been
demonstrated to be sufficient for the measurement of calcium signals (Ruchala,
unpublished data), along with .15µg EGFP as a reporter of transfection. For
hNET, CaV1.3 is used in place of CaV1.2, as hNET, upon substrate challenge
and for intriguing and unclear reasons, often fails to couple to calcium signals
when CaV1.2 is used as a reporter. I found it crucial not to use more than .5µg of
CaV1.3 per 24 wells, for the use of more plasmid gave rise to cells that fire
spontaneous, rhythmic calcium signals. For hNET, the α2δ and β3 subunits are
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co-transfected with CaV1.3 in a ratio of 1 : 1 : 1. After allowing the transfection
reagent to function for 4-7 hours, fresh media with 1µg/mL doxycycline is
exchanged for the old media, and cells are stored for 62-72 hours at 37 degrees
Celsius before experimentation. On the day of experimentation, fura-2AM (Life
Technologies), having been dissolved in Pluronic-F27 solution within DMSO, is
unfrozen and pipetted into an aliquot of imaging solution (IS). The IS, prepared
previously, consists of (in mM): 130 NaCl, 4 KCl, 2CaCl2, 1MgCl2, 10 HEPES,
and 10 glucose, adjusted to pH 7.4 via NaOH. The final concentration of the ISfura-2 mixture is 5.5µM fura-2, and 50µL is exchanged for the DMEM of each
well. Cells are subsequently incubated at 37 degrees Celsius for 30 minutes to
allow membrane permeation of the dye. After incubation, the fura-2 solution is
exchanged for IS, and cells are allowed to equilibrate for 20-30 minutes at room
temperature prior to recording. Solutions of compounds are prepared freshly for
each experiment by serial dilution.
Microscopy is conducted via an Olympus IX70 microscope, outfitted with a
Polychrome V light source and a Luca S digital camera. The perfusion system is
automatic, and controlled by Till Photonics’ Live Acquisition software. Cells are
perfused for at least 30 seconds prior to the initiation of recording with IS warmed
to 35 degrees Celsius by a ThermoClamp-1 heater (AutoMate Scientific).
At the initiation of all recordings, there is a 10 second perfusion of IS in
order to establish a steady baseline. After 10 seconds has elapsed, the control
pulse, which in all cases is 10µM dopamine, is initiated for 5 seconds. Substrateinduced, transporter-mediated current couples to the activation of the co-
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transfected Cav1.2 or Cav1.3 channels, and subsequent Ca++ permeation gives
rise to a hypsochromic shift in the emission spectrum of fura-2, which is
measured as a Ca++ signal (please see the next section, and Figure M2). A 30second period of drug washout ensues, during which time the endogenous Ca++
pumps and exchangers of the HEK cell restore the intracellular environment to
near-baseline Ca++ concentrations. Subsequently: for a trial with a known
substrate, there is a 5-second experimental pulse of the substrate of interest, and
the substrate trial ends after a final 30-second washout. For a trial with a known
inhibitor, there is a 30 second period of administration of the inhibitor dissolved in
IS at the concentration of interest. This 30-second period of administration of
pure inhibitor is executed to control for any kinetic differences in inhibition
between different inhibitor species. After this 30-second period of administration
of pure inhibitor, there is an experimental pulse of IS mixed with the inhibitor at
the same concentration and mixed with 5µM dopamine. Thus, inhibition
manifests indirectly, as the inhibitor-mediated diminution of substrate-induced
Ca++ signals.
We use a high numerical aperture objective to maximize the collection of
photons: Olympus 20X .8NA oil. Fura-2 signals were collected by switching the
excitation wavelength between 340nm and 380nm at a rate of 6Hz—for a
ratiometric acquisition frequency of 3Hz—by means of an LP490 dichroic mirror
while monitoring the emission at 510nm. EGFP fluorescence (excitation
wavelength 490nm) was monitored as a reporter of transfection. I choose cellular
regions of mid-confluency with a range of transfection efficiency for trials. Dose-
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response experiments for each experimental compound are repeated at least 2
times, and each dose-response experiment is conducted with an independently
transfected 96-well plate. Ratiometric files of each successful trial were stored on
the computer’s data drive for future analysis offline via Live Acquisition Offline
Analysis software.
1.1 Recording of Ca++ Signals
Drug-induced rises of the intracellular concentration of Ca++ are measured
by monitoring the ratio of the number of photons which the Ca++-sensing dye
fura-2 (Figure M1) emits during excitation at 340nm and excitation at 380nm.
Figure M1: Fura-2 molecular
structure. Rendering from
the Public Domain.

Please see Figure M2 for a schematic rendering of how dye-mediated emission
of photons is correlated to intracellular rises in Ca++. Upon Ca++ binding to fura-2,
the Ca++ cation disrupts the conjugation between a lone pair of electrons on
nitrogen and the ring system to which the nitrogen is bonded; this disruption of
the electronic network of the chromophore gives rise to the dye’s hypsochromic
shift (Grynkiewicz, Poenie, and Tsien, 1985). Cell biological research uses fura-2
ubiquitously; as of this writing, the paper reporting its discovery (Grynkiewicz,
Poenie, and Tsien, 1985) has been cited 20,683 times. Fura-2 is very useful:
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because its signals are calculated as a ratio of the emission amplitudes at two
different excitation frequencies, there is a built-in control for differences in fura-2
concentration differences between cells, for the length of the path light takes as it
passes through the system (e.g., a control for thicker or thinner sections of cell
membrane), for the intensity of the light used for excitation, and for the “absolute
sensitivity of the instrument” (Grynkiewicz, Poenie, and Tsien, 1985). In other
words, the same concentration of Ca++ evolves the same ratiometric signal
whether there are 100 or 1,000 molecules of fura-2 within the cell, since the
signal of fura-2 unbound to Ca++ effectively cancels by dividing into itself when
factored into the final ratio of fluorescence340nm/380nm / fluorescencebaseline, since
the ratio of its emission at 340nm / 380nm never changes from baseline during
the trial.
1.2 Analysis of data
A trial is considered good and is analyzed only if the cell under study
responds quickly and robustly to the internal control, which in all cases is an
initial application of 10µM dopamine. The ratiometric values, defined as the ratio
of the fluorescence at 340 nm / 380nm to the baseline fluorescence, from the
cells demonstrating robust responses to the internal control are collected from all
time points and fed into a data analytics spreadsheet within Microsoft Excel. For
a substrate trial, the peaks for the 10µM dopamine control and for the variable
concentration of drug are defined as the baseline-subtracted mean of the value
of the 340nm/380nm ratio from 16-17 seconds (control) and from 51.6-52.3
seconds (drug). The peak for the control pulse is defined as beginning 6 seconds
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after drug application. The peak for the experimental drug application is defined
as beginning 6.6 seconds after drug application. This offset is implemented in
order not to deflate artificially the value of the peak during application of low and
moderate concentrations of drugs, which tend to be slower in onset compared to
10µM dopamine. Both of these peaks are defined with the aim to measure the
steady-state component of the Ca++ signal. For trials using the inhibitor protocol,
the peak of the 10µM dopamine control is defined equivalently, as the baselinesubtracted mean of the 340nm/380nm ratio from 16-17 seconds, and the
experimental pulse of 5µM dopamine mixed with a concentration of the drug of
interest is defined as the baseline-subtracted mean of the 340/380nm ratio from
80.8 seconds to 81.8 seconds. For each cell, the experimental peak is divided by
the control peak, yielding a fraction; the mean of these fractions represents the
mean baseline-subtracted fraction of the experimental peak divided by the
control peak for each concentration. These fractions—for both substrate and
inhibitor trials—are fit to the following equation using Prism:
Equation (1) Y(x) = (Ymax) / 1 + 10exp[(logEC50 – logx) * n]
In this equation, x is the concentration of experimental compound; Y(x) is the
measured response; EC50 is the concentration of compound that gives rise to the
half-maximal response; and n is the Hill slope parameter. Data for each
concentration of an experimental compound is pooled from at least n = 18 cells
(for clearly saturating concentrations of experimental compound), and, more
typically, at least n = 30 cells.

55
To calculate the cumulative Ca++ traces for each concentration, traces are
normalized to 1 by subtracting 1 (the baseline) from the mean of each point of
the time dimension, then dividing by the (maximum value of the peak of the
internal dopamine control -1). Thus, the unitary peak is defined as the maximum
value of the mean peak of the 10µM dopamine control, and all other points in the
time dimension are defined relative to this peak.
2. Immunofluorescence, confocal microscopy, and N-SIM super-resolution
microscopy
2.1: Immunostaining and preparation of slides
HEK cell lines stably expressing hDAT are plated on cover slips and
transfected with mVenus-Cav1.2 via the previously detailed procedure. Professor
José-Miguel Eltit prepared the mVenus-Cav1.2 construct by cloning mVenus, a
derivative of YFP engineered to emit photons more efficiently, into the N-terminal
tail of Cav1.2. Subsequently the exchange of the transfection media for fresh
media with 1µg/mL doxycycline induces hDAT expression. For N-SIM superresolution microscopy, it is required to plate cells on #1.5 coverslips, of 170µM
thickness. After incubating the cells in standard cell culture conditions for 62-72
hours, the cover slips are removed from DMEM and fixed in ~3mL of cold
anhydrous methanol in a 6-well plate (Corning). After methanol fixation, which
functions to dissolve the cell membrane while fixing the position of cellular
species of protein, the cells are washed, quickly, with isotonic phosphatebuffered saline (PBS). The PBS wash is repeated 2 additional times, leaving the
cover slips for 10-15 minutes each time.
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Rat monoclonal-anti DAT (Santa Cruz Biotechnology, Catalog# sc-32258)
is prepared at a dilution of 1µL antibody : 500µL PBS + 1% bovine serum
albumin (BSA). After washing, the cover slips are placed, facing downward, on
50µL of the primary antibody mixture pipetted onto Parafilm-covered, round
plastic cassettes. These cassettes are stored overnight at 4 degrees Celsius in
100mm culture dishes (Corning), in which humidity is maintained by the addition
of Kimwipes soaked in double-deionized water. The next day, the cover slips are
washed 3 times in PBS + 1%BSA, leaving the cover slips for 10-15 minutes each
time. The secondary antibody, Alexa Fluor 555 goat anti-rat IgG (Invitrogen, Cat#
A21434), is prepared at a dilution of 1µL antibody : 1,000µL PBS + 1% BSA. The
cells are placed, facing upward this time, on newly wrapped, Parafilm-covered
round plastic cassettes, and 70-80µL of the secondary antibody solution is
pipetted on top of the cover slips. The cells are stored at room temperature for
just 1.5 hours. The cover slips are washed one time with PBS + 1% BSA; then
they are washed again with PBS + 1% BSA with DAPI, at a concentration of
about .66µM. Then the cover slips are washed a third time with PBS + 1% BSA.
Finally, cover slips are mounted on glass slides using Prolong Diamond anti-fade
mounting media (Thermofisher). This mounting media has an index of refraction
of 1.47 upon curing, and the prepared slides are left in the dark for ~48 hours
prior to experimentation. Serendipitously, we discovered what several
microscopists had reported previously: the fluorophore of mVenus functions even
subsequent to methanol fixation, despite the biological violence inherent to this
process. Thus, no immunostaining of the mVenus-Cav1.2- construct was
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necessary.
2.2: Confocal microscopy
In order to gauge the success of the immunostaining, specimens are
imaged by means of a Zeiss 710 confocal microscope using a 60x lens. An
example of the resulting micrograph is displayed in Figure 2. The one advantage
that the confocal imaging modality has over the N-SIM super-resolution modality
is the ability to image in the z-plane. N-SIM super-resolution microscopy tends to
photobleach the fluorophore of mVenus-Cav1.2 even during relatively short
periods of exposure to the 488nm laser.
All microscopy was performed at the VCU Department of Anatomy and
Neurobiology microscopy facility, supported, in part, by funding from NIH-NINDS
Center Core Grant 5 P30 NS047463 and, in part, from the NIH-NCI Cancer
Center Support Grant P30 CA016059.
2.3: N-SIM super-resolution microscopy
N-SIM (Nikon structured illumination microscopy) is a modality, developed
over the past 25 years, that exploits tricks of the physics of photons to surpass
the diffraction limit of image resolution, which exists owing to the finite,
nanometer-range wavelength of visible length. In order to surpass this limit, one
must construct a system that is able to collect a degree of extra information from
the photons that a sample emits. The strategy implemented in this study is
structured illumination microscopy, conducted with Nikon’s 100x TIRF lens. This
strategy gleans extra information from the sample by means of shaping structure
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into the illuminating light itself. This patterned light illuminates the sample, and its
patterns are superimposed on the patterns inherent to the sample. This
multiplicative superimposition of patterns gives rise to moiré fringes, like those
perceptible when two sections of screening are superimposed. Crucially, “moiré
fringes can be resolved even if both patterns are too fine” to resolve otherwise
(Agard, 2013). In other words, and by rough analogy, the interference pattern
functions as a filter for photons that otherwise escape detection. The emitted light
contains 3 superimposed ”information components” that are shifted relative to
each other as an inverse function of the length of the stripe unit comprising the
moiré fringes (Agard, 2013). These extra information components exist in
diffraction space, or Fourier space, and each maps unique information into the
observable region. By means of recording the emission pattern at 3 separate
angles of illumination—120, 240, and 360 degrees—there is sufficient additional
information about the relation of the three sets of information components that a
computer algorithm can reconstruct the spatial origin of each information
component. This process is then repeated in 2 additional directions in order to fill
in the rest of the space around the observable region, which is circular in shape.
Ultimately, the computer unscrambles all of the extra information into a superresolution image. The process of mapping additional information from 3
directions into the observable region explains why the Fourier transform images
depicted in Figure 1C take the shape of a hexagon: each of the 3 lines through
the origin represents the additional information gained in the 3 directions of this
diffraction space. The net result of all these tricks and processing is an increase
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in image resolution by a factor of 2.
3. Two-electrode voltage clamp (TEVC)
Stage V or VI oocytes of Xenopus laevis frogs are injected with 32.2ng of
cRNA coding for dDAT, and experiments are performed after the injected
oocytes are incubated in Ringer’s solution augmented with sodium pyruvate (550
µg/mL), streptomycin (100 µg/mL), and tetracycline (50 µg/mL), along with 5%
dialyzed horse serum, at 17 degrees Celsius for about 90 hours. The external
solution for recording consists of (in mM): 120 NaCl, 7.5 HEPES, 5.4 K+
gluconate, 1.2 Ca++ gluconate, pH adjusted to 7.4 with NaOH. For two-electrode
voltage clamp experiments, fresh electrodes are pulled and filled with 3M KCl,
then fitted to the current injecting and voltage measuring apparatuses. Electrodes
with input resistance of 1-5 MΩ are gently inserted into the oocyte until a drop in
the reading of the voltage-measuring electrode indicates that the vitelline layer
has been infiltrated. Subsequently, I gently perfuse the oocytes with external
solution, then clamp it to a potential of -58 to -60mV. Perfusion is continued until
the current-injecting electrode indicates a steady baseline, at which point drug
administration experiments are initiated. I attempted the same experiments in
oocytes injected with hDAT cRNA, yet I failed to encounter any oocytes that
responded to the control pulse of 5µM dopamine. In general, and for unclear
reasons, Xenopus oocytes more quickly and robustly express dDAT compared to
hDAT.
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III. Specific aims
1. It is known that Cav1.2 clusters together in the myocardium, an
organization that promotes positive cooperativity, as Ca++ flux via a subset of
channels increases the probability of Ca++ flux via the rest of the cluster (Dixon et
al., 2015). Further, hDAT is known to distribute to distinct regions in the plasma
membrane. Therefore, specific aim 1 was to investigate the relative cellular
spatial relationship of hDAT and Cav1.2 by means of immunostaining of hDAT in
conjunction with fluorescent labeling of Cav1.2 by tagging it at the N-terminus
with a fluorescent protein, in this case mVenus.
2. Specific aim 2 was to elucidate the pharmacodynamic effects of N-alkyl
4-Me AMPH N-alkyl chain extension at the human dopamine transporter and
human norepinephrine transporter by means of the calcium fluorescence assay.
3. It is known that dDAT represents an ancestral catecholamine
transporter that behaves in certain manners like hDAT and in certain manners
like hNET. Therefore, specific aim 3 was to assess the pharmacodynamic effects
of N-alkyl 4-Me AMPH N-alkyl chain extension at this hybrid transporter.
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IV: Results and figures
1. Methodological schemata of the Ca++ fluorescence
assay, pages 66-67.
2. Micrographs of immunofluorescence studies, pages 68-72.
3. Dose versus response curves and cumulative Ca++ traces for
compounds under study, pages 74-87.
4. Tables of EC50 and IC50 values for compounds under study,
in addition to statistics and a summary schematic, pages 88-90.
5. TEVC electrophysiological traces of drug-induced dDAT
currents, pages 91-92.
Immunostaining of hDAT within HEK cells stably expressing hDAT, in
conjunction with the preserved fluorophore of mVenus-Cav1.2, allowed the
assessment of the cellular localization of these two proteins. By means of laserscanning confocal microscopy, it is evident that both proteins tend to occupy
specific regions of the cell membrane; further, it is evident that at some loci these
regions are directly apposed, while at other loci the two proteins occupy distinct
domains (Figure 1). By means of N-SIM super-resolution microscopy, an
improvement in resolution by about a factor of 2 allows a more precise study of
the respective membrane and intracellular localization of these two proteins.
Figure 2 depicts a HEK cell stably expressing hDAT (red) and transfected with
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mVenus-Cav1.2 (green) as captured by traditional confocal modality (right) and
by N-SIM super-resolution microscopy. The two micrographs are presented at an
equivalent scale in order to demonstrate the improvement in resolution relative to
confocal afforded by N-SIM super-resolution microscopy.
In Figure 3, it is evident that hDAT and mVenus-Cav1.2 tend to occupy
exclusive regions within the cell membrane, although there do exist interspersed
regions of very close apposition (Figure 3A). Figure 3B depicts a HEK cell stably
expressing hDAT and transfected with mVenus-Cav1.2 that is captured while
undergoing telophase. Figure 4 depicts an N-SIM super-resolution study of the
membrane co-localization of hDAT (red) with mVenus-Cav1.2 (green); Figure 4C
depicts the merging of these two channels, while Figure 4D depicts, in white
streaks, the areas of the membrane where hDAT and mVenus-Cav1.2 are
directly apposed. Figure 5 emphasizes the fact that, while hDAT and mVenusCav1.2 may share overlapping plasmalemmal domains, they tend to traffic by
separate routes within the intracellular environment.
To determine the values of the EC50 for the enantiomers of the N-alkyl
analogs of 4-Me AMPH at hDAT and hNET, we conducted dose versus response
experiments with each drug at each transporter by means of the calcium
fluorescence assay, which is depicted schematically in Figure M2. Figure M3
depicts a typical trial extracted from the cumulative dose versus response data.
Figure 6 depicts the dose v. response relationship of the enantiomers of N-Me 4Me AMPH at hDAT as measured by the calcium fluorescence assay. Fitting the
data to the modified Hill equation (Equation 1), the EC50 is measured at 263.3 +/-
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20.95 nM for (S)-N-Me 4-Me AMPH, and at 2043 +/- 151.3nM for (R)-N-Me 4-Me
AMPH. This difference in potency between the two enantiomers at hDAT is
statistically significant (one-way ANOVA, Tukey’s multiple comparison test, P <
.001). The Hill slope of (R)-N-Me 4-Me AMPH is 1.408 +/- .1486, and its
maximum efficacy is .7955. The Hill slope of (S)-N-Me 4-Me AMPH is 1.055 +/.09652, and its maximum efficacy is 1.197. Figures 7 and 8 depict the cumulative
calcium traces pooled from the dose versus response experiments at each
concentration. For each concentration, the control pulse of 10µM dopamine is
normalized to 1, and all experimental pulses of drug are measured relative to this
initial control. Note that in Figure 8, upon transition from 3µM to 10µM (S)-N-Me
4-Me AMPH, the ensuing Ca++ signal decays more slowly subsequent to the
wash out of the experimental drug.
To quantify the difference in the kinetics of the decay of the Ca++ signal
between (R)- and (S)-N-Me 4-Me AMPH at hDAT, the first derivative of each
point in the time dimension was calculated for each enantiomer at 10µM (Figures
9 and 10). There is a marked difference in the value of the negative slope during
the period of drug wash out: the mean value of the negative slope over the
interval 55.01 to 56.01 seconds for (R)-N-Me 4-Me AMPH (-.0338) is about 3
times greater than the value of the negative slope over the same interval for (S)N-Me 4-Me AMPH (-.0121).
It was found that upon N-Me 4-Me AMPH N-alkyl chain extension from NMe to N-Et, the resulting compound no longer gave rise to the Ca++ signal at
hDAT typical of monoamine transporter substrates; therefore, we subjected the

64
enantiomers of N-Et 4-Me AMPH to the inhibitor version of the Ca++ fluorescence
protocol in order to assay its propensity to block the Ca++ signals mediated by
5µM dopamine. Figure 11 depicts the dose v. response relationship of the
enantiomers of N-Et 4-Me AMPH at hDAT. Fitting the data to Equation 1, the IC50
of (R)-N-Et 4-Me AMPH is calculated at 16,756 +/- 2292nM. The IC50 of (S)-N-Et
4-Me AMPH is calculated at 748.2 +/- 76.77nM. These two values of the IC50 are
significantly different (unpaired t-test, P < .0001). Figures 12 and 13 depict the
cumulative Ca++ traces of the enantiomers of N-Et 4-Me AMPH at hDAT. For
hDAT, in all cases Cav1.2 is used as the reporter for monoamine ion flux. Table 1
presents the fitting parameters of the dose v. response curves of all drugs at
hDAT.
To assess inter-transporter differences in pharmacodynamic properties of
the enantiomers of the N-alkyl analogs of 4-Me AMPH, we conducted dose
versus response experiments of the drugs at hNET. Figure 14 depicts the dose v.
response relationship of the enantiomers of N-Me 4-Me AMPH at hNET. Fitting
the data to Equation 1, the EC50 is measured at 96.02 +/- 11.90nM for (R)-N-Me
4-Me AMPH and at 55.51 +/- 5.227nM for (S)-N-Me 4-Me AMPH. The Hill slope
for (R)-N-Me 4-Me AMPH is measured at .9381 +/- .09534, and its maximum
efficacy is 1.055. The Hill slope for (S)-N-Me 4-Me AMPH is measured at 1.903
+/- .2414, and its maximum efficacy is .927. Figures 15 and 16 depict the
cumulative Ca++ traces of the enantiomers of N-Me 4-Me AMPH at hNET. Figure
17 depicts the dose v. response relationship of the enantiomers of N-Et 4-Me
AMPH, which are hNET substrates. The EC50 is measured at 1,168 +/- 211.8nM
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for (R)-N-Et 4-Me AMPH and at 565 +/- 77.71nM for (S)-N-Et 4-Me AMPH. The
values of the EC50 for (R)- and (S)-N-Et 4-Me AMPH at hNET are significantly
different (one-way ANOVA, Tukey’s multiple comparison test, P < .001). The Hill
slope for (R)-N-Et 4-Me AMPH is measured at 1.126 +/- .2562, and its maximum
efficacy is .6751. The Hill slope for (S)-N-Et 4-Me AMPH is measured at 1.094 +/.1531, and its maximum efficacy is .875. Figures 18 and 19 depict the cumulative
Ca++ traces of the enantiomers of N-Et 4-Me AMPH at hNET. For hNET, in all
cases Cav1.3 is used as the reporter for monoamine ion flux. Table 2 presents
the fitting parameters of the dose v. response curves of all drugs at hNET. Table
3 presents statistics on inter-transporter and inter-substrate potency differences.
Figure 20 summarizes the pharmacodynamic profiles of all drugs.
To probe the effects of N-Me 4-Me AMPH N-alkyl chain extension at a
transporter known to harbor both hDAT-like and hNET-like characteristics, the
effects of the enantiomers of N-Me 4-Me AMPH and the effects of (S)-N-Et 4-Me
AMPH were assessed at dDAT by means of the two-electrode voltage clamp
technique. A control pulse of 5µM dopamine is applied at the beginning of each
experiment. Figure 21 demonstrates that 10µM both enantiomers of N-Me 4-Me
AMPH are dDAT substrates, and (S)-N-Me 4-Me AMPH (~100nA) is about 5
times more efficacious than (R)-N-Me 4-Me AMPH (~20nA). Further, 10µM (S)N-Et 4-Me AMPH behaves as a relatively efficacious substrate at dDAT, giving
rise to currents of about 90nA (Figure 22).
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Figure M2: schematic rendering of how substrate-induced transporter currents give rise to
Cav1.2-reported Ca++ signals by means of fura-2 ratiometric dye. Monoamine transporter
substrates give rise to a monoamine transporter-mediated, depolarizing current. This
current activates the voltage gated Ca++ channel, L-type 1.2 (Cav1.2). Then, Ca++ binding
effects a hypsochromic shift in the fura-2 emission spectrum, and the ratio of emission in
response to excitation at 340nm / 380nm increases. Image of HEK cells modified from the
Database Center for Life Sciences under a Creative Commons Attribution 3.0 Unported
license.
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Figure M3: A. Montage of a picturesque substrate trial at hNET using 10µM dopamine
(control) followed by 1µM of test compound, in this case 1µM (S)-N-Me 4-Me AMPH. B.
The F340/380 / F0 Ca++ signal of a typical region of interest, which is highlighted with a hotpink dot. C. Cells revealing positive transfection, as judged by the EGFP signal monitored
at 490nm.
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Figure 1: Stably expressing hDAT (red) HEK cells co-transfected with mVenus-Cav1.2
(green), imaged with the confocal modality. A. hDAT channel. B. mVenus-Cav1.2
channel. C. Merge of hDAT and mVenus-Cav1.2 channels.
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Figure 2: Comparison of the resolution capabilities of confocal (left) with N-SIM superresolution microscopy (right). It is clear that the N-SIM super-resolution modality
markedly clarifies the plasmalemmal domains of hDAT (red) and mVenus-Cav1.2 (green)
compared to the confocal modality.
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Figure 4: N-SIM
super-resolution
image of HEK cells
stably expressing
hDAT (red) (A),
with co-expression
of mVenus-Cav1.2
(green) (B). C.
Merge of panels A
and B. D. depicts
overlapping
regions of hDAT
and mVenusCaV1.2 in white.
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Figure 5: Additional co-localization study of HEK cell stably expressing hDAT (red)
co-transfected with mVenus-Cav1.2 (green). A. hDAT channel. B. mVenus-Cav1.2
channel. C. Merge of hDAT and mVenus-Cav1.2 channels. D. White speckles reveal
areas of hDAT co-localization with mVenus-Cav1.2. Note that within the intracellular
environment, despite the plethora of both proteins, there is virtually no co-localization
between the two. Yet, there is evident co-localization at the cell membrane.
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Dose versus response curves and cumulative Ca++ traces
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Figure 6: Dose v. response of enantiomers of
N-Me 4-Me AMPH at hDAT using CaV1.2 as
the reporter. Data are displayed as mean +/s.e.m.
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Figure 7: Cumulative calcium traces for (R)-N-Me 4-Me AMPH
at hDAT, summed from all cells assayed at the given
concentration of compound. CaV1.2 is used as the reporter.
Hash bars indicate the s.e.m. of each concentration.
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Figure 8: Cumulative calcium traces for (S)-N-Me 4-Me
AMPH at hDAT, summed from all cells assayed at the given
concentration of compound. CaV1.2 is used as the reporter.
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Figure 9: The first derivative of the mean in the time
dimension of all trials of 10µM (R)-N-Me 4-Me AMPH at
hDAT. Please see discussion.
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Figure 10: The first derivative of the mean in the time
dimension of all trials of 10µM (S)-N-Me 4-Me AMPH at
hDAT. Please see discussion.

79

hDAT, fura-2
1.0

0.8

(R)-N-Et 4-Me AMPH

F/F10mM DA

(S)-N-Et 4-Me AMPH
0.6

0.4

0.2

0.0

1

10

100

1000

10000

100000

nM compound

Figure 11: Dose v. response of enantiomers of N-Et
4-Me AMPH at hDAT using Cav1.2 as the reporter.
Data are displayed as mean +/-s.e.m.
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Figure 13: Cumulative calcium traces for (S)-N-Et 4-Me
AMPH at hDAT, summed from all cells assayed at the
given concentration of compound. Cav1.2 is used as the
reporter.
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Figure 14: Dose v. response of enantiomers of N-Me 4Me AMPH at hNET using Cav1.3 as the reporter. Data
are displayed as mean +/-s.e.m.
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Figure 15: Cumulative calcium traces for (R)-N-Me 4-Me
AMPH at hNET, summed from all cells assayed at the given
concentration of compound. Cav1.3 is used as the reporter.
Note that signals are perceptible at concentrations of
compound as low as 1nM.
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Figure 17: Dose v. response of enantiomers of
N-Et 4-Me AMPH at hNET using Cav1.3 as the
reporter. Data are displayed as mean +/-s.e.m.

86

:45'+, ;<=>3?
!"#$
%"#$
!#$
%#$
!""&$
%""&$

++

Normalized Ca Signal

1.0

0.5

0.0

%"#$, ./
0

5

01234356, 73$*, /$89

10 15 20 25 30 35 40 45 50 55 60 65 70 75 80

'()*+, Figure 18: Cumulative calcium traces for (R)-N-Et 4-Me
AMPH at hNET, summed from all cells assayed at the given
concentration of compound. Cav1.3 is used as the reporter.
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hDAT
EC50 or IC50, nM
(R)-N-Me 4-Me
AMPH
(S)-N-Me 4-Me
AMPH
(R)-N-Et 4-Me
AMPH
(S)-N-Et 4-Me
AMPH

Hill slope

Maximum
efficacy relative
to 10µM
dopamine

88
Minimum
number of cells
assayed

2,043 +/- 151.3nM

1.408 +/- .1486

.7955

25

263.3 +/- 20.95nM

1.055 +/- .09652

1.197

18

16,756 +/- 2292nM

-.5946 +/- .0700

--

47

748.2 +/- 76.77nM

-.8226 +/- .0656

--

30

Table 1: Fitting parameters for the dose versus response curves for all N-alkyl 4-Me AMPH compounds at
hDAT, displayed as +/- the s.e.m.

hNET
EC50 or IC50, nM
(R)-N-Me 4-Me
AMPH
(S)-N-Me 4-Me
AMPH
(R)-N-Et 4-Me
AMPH
(S)-N-Et 4-Me
AMPH

Hill slope

Maximum
efficacy relative
to 10µM
dopamine

Minimum
number of cells
assayed

96.02 +/- 11.90nM

.9381 +/- .09534

1.055

26

55.51 +/- 5.227nM

1.903 +/- .2414

.927

23

1,168 +/- 211.8nM

1.126 +/- .2562

.6751

31

565.0 +/- 77.71nM

1.094 +/- .1531

.875

41

Table 2: Fitting parameters for the dose versus response curves for all N-alkyl 4-Me AMPH
compounds at hNET, displayed as +/- the s.e.m.
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Transporter
hDAT
hNET

(R)-N-Me 4-Me
AMPH
***, ###

(S)-N-Me 4-Me
AMPH
***, ###
***, ###

(R)-N-Et 4-Me
AMPH

(S)-N-Et 4-Me
AMPH

***

***, ###, %, $$

Table 3: one-way ANOVA with Tukey’s multiple comparison test was used to calculate significant
differences in affinities (EC50) of N-alkyl 4-Me AMPH substrates at hDAT and hNET.
*** = EC50 significantly different at P < .001 compared to EC50 of (R)-N-Me 4-Me AMPH at hDAT.
### = EC50 significantly different at P < .001 compared to EC50 of (R)-N-Et 4-Me AMPH at hNET.
% = EC50 significantly different at P < .05 compared to EC50 of (S)-N-Me 4-Me AMPH at hNET.
$$ = EC50 significantly different at P < .01 compared to EC50 of (R)-N-Et 4-Me AMPH at hNET.
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Figure 20: Summary diagram of the pharmacodynamic profiles of the enantiomers of
N-Me and N-Et 4-Me AMPH at both hDAT and hNET. N-Me to N-Et N-alkyl chain
extension takes a substrate to an inhibitor at hDAT, and both compounds are
substrates at hNET.
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Figure 21: Both enantiomers of N-Me 4-Me AMPH are substrates at the Drosophila
melanogaster dopamine transporter (dDAT).
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Figure 22: (S)-N-Et 4-Me AMPH is a substrate of the Drosophila
melanogaster dopamine transporter (dDAT), a transporter known to
behave as an hDAT / hNET hybrid. Note the off-spike (thin arrow) and the
persistent current (thick arrow) (please see Discussion).
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V. Discussion
The results of the present study yield vital pharmacodynamic metrics for a
heretofore-unstudied class of enantiomerically pure amphetamine analogs, in
addition to insights into the spatial co-localization of the hDAT with mVenusCaV1.2 at the plasmalemma. The compounds under study represent the β-deketo
analogs of mephedrone (4-methyl-methcathinone) and 4-methyl-ethcathinone (4MEC), both of which compounds have been popularly sold and ingested as
“research chemicals.” Further, the compounds are N-alkyl analogs of 4-methyl
amphetamine (4-Me AMPH), which also has a history of human use, with
involvement in at least 5 fatalities in Europe (Blanckaert, 2012).
As expected from the results of Ca++ fluorescence and TEVC studies of
the racemic mixtures of these compounds, there occurs an intriguing switch in
the pharmacological action of the compound upon expansion of the N-alkyl chain
from a methyl (N=1 carbon) to an ethyl (N=2 carbon). Upon N-alkyl methyl to
ethyl extension, N-alkyl 4-Me AMPH switches from a substrate at hDAT to an
inhibitor at hDAT. This switch at hDAT occurs between the methylated and
ethylated versions of both the (R) and the (S) enantiomers. Curiously, Tessel and
Rutledge (1975) found that N-Et AMPH, a one-time candidate as an anorectic
drug, gave rise to release of both tritiated dopamine and norepinephrine from
isolated striatal tissue of the rat. These results may indicate that both the
methylation at the 4-position and at the N-Me position is necessary to induce the
pharmacological switch from substrate to inhibitor at hDAT. A more likely
explanation, however, may be that the striatal preparation used in the study
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contained the enzymes necessary to dealkylate N-Et AMPH to AMPH, a typical
in vivo fate of N-Et AMPH (Kraemer and Maurer, 2002).
Interestingly, (S)-N-Et 4-Me AMPH is a moderately potent inhibitor at
hDAT (IC50 = 748.2nM), while (R)-N-Et 4-Me AMPH is quite weak (IC50 =
16,756nM). These values are consistent with a model in which (S)-N-Et 4-Me
AMPH binds at a specific site of hDAT, likely the S1 site. However, due to the
–CH2 expansion of the N-alkyl chain, steric clash, perhaps at a bulky single
amino acid residue at the S1-site, blocks (S)-N-Et 4-Me AMPH from permeating
the transporter. Conceptualizing hDAT as a ligand-gated ligand-ion channel, this
steric clash of (S)-N-Et 4-Me AMPH at the transporter prevents the coordinated
isomerization of the transporter’s network of amino acids necessary for the gating
of the channel-like mode of function. Meanwhile, (R)-N-Et 4-Me AMPH functions
like an inhibitor by means of mass action, diverting dopamine substrate
molecules from a path to the core of the transporter. Also as expected from the
substantial dataset of the pharmacology of the amphetamines, the (S)
enantiomer is more potent than the (R) enantiomer in all cases at hDAT, both as
a substrate and as an inhibitor. (S)-N-Me 4-Me AMPH is about 10 times more
potent than (R)-N-Me 4-Me AMPH as an hDAT substrate. Finally, at hDAT, there
is a concentration-correlated decrease in baseline fluorescence upon
administration of both (R)- and (S)-N-Et 4-Me AMPH (please see Figures 11 and
12). This phenomenon is reminiscent of the manifestation of the leak current as a
hyperpolarizing fleck subsequent to the administration of an inhibitor to
monoamine transporter-expressing oocytes during TEVC experiments.
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Remarkably, despite the methyl to ethyl N-alkyl chain extension giving rise
to a switch from substrate to inhibitor at hDAT, both enantiomers of both N-Me
and N-Et 4-Me AMPH are substrates at hNET. Thus the enantiomers of N-Et 4Me AMPH represent a rarity: an inhibitor totally selective for hDAT over hNET
(Andersen et al., 2015). There is a ~10 fold reduction in potency as a substrate at
hNET upon N-alkyl chain extension from a methyl to an ethyl, and this ~10 fold
reduction in potency is observed with both (R) and (S) enantiomers. Notably,
there is a statistically significant reduction of efficacy after elevation from 10µM
(S)-N-Et 4-Me AMPH to 30µM (S)-N-Et 4-Me AMPH (unpaired t-test, P = .0002),
and a non-statistically-significant drop of efficacy across the same concentration
interval with (R)-N-Et 4-Me AMPH.
The difference in potency between the two enantiomers of N-Me 4-Me
AMPH is markedly lesser at hNET than at hDAT; in this case, at hNET, (S)-N-Me
4-Me AMPH (EC50 = 55.47nM) is measured to be about 2 times more potent than
(R)-N-Me 4-Me AMPH (EC50 = 96.02 nM). These results agree well with those of
previous studies, e.g. Richelson and Pfenning (1984), who measured (R)amphetamine potency to be lesser than (S)-amphetamine potency by a factor of
1.8 in the inhibition of tritiated norepinephrine uptake by rat brain synaptosomes.
These low nanomolar values of the EC50 indicate that both enantiomers of N-Me
4-Me AMPH are very potent substrates of hNET. Furthermore, (R)-N-Me 4-Me
AMPH is a remarkably selective hNET substrate, showing 2043nM (hDAT) /
96.02nM (hNET) = 21.27-fold selectivity for hNET over hDAT. (S)-N-Me 4-Me
AMPH shows hNET selectivity also, calculated as 263.3nM (hDAT) / 55.47nM
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(hNET) = 4.74 fold selectivity for hNET over hDAT. This interpretation stands
even bearing in mind that the hDAT data is derived using Cav1.2 as a reporter,
and the hNET data is derived using Cav1.3 as a reporter, since Cameron et al.
(2015) find that (S)-amphetamine is measured as slightly more potent using
Cav1.3 (EC50 = 102 +/- 16nM) than using Cav1.2 (EC50 = 144 +/- 11nM) as a
reporter, and this potency differential fails to achieve statistical significance.
The hNET selectivity of the N-Me 4-Me AMPH enantiomers is intriguing in
light of a 1988 case study from Great Britain (Bal, 1988), which documents the
physiological aftermath of presumably racemic 4-Me AMPH ingestion. A man
presented to the emergency department, having insufflated 4-Me AMPH that he
believed to be typical amphetamine. His heart rate was 150 beats per minute,
and his blood pressure was 200/120 mm Hg. Following administration of the
selective beta-adrenergic blocker practolol, the man’s blood pressure surged to
240/160 mm Hg, and it did not stabilize until the next morning. He survived,
experiencing “considerable anxiety” resulting from this episode. These
physiological effects suggest that this man experienced a
hypernorepinephrinergic crisis due to 4-Me AMPH intoxication. This result is not
surprising given the potent and selective norepinephrinergic profiles of the
enantiomers of the N-methylated analog of 4-Me AMPH under study. It will be
very interesting to measure the potency of (R)-N-Me 4-Me AMPH at hSERT, and
(R)-N-Me 4-Me AMPH could function as a potent and selective hNET substrate
and norepinephrine releaser for in vivo experiments.
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An interesting phenomenon emerges during Ca++ fluorescence
experiments at hDAT using the enantiomers of N-Me 4-Me AMPH. That is, there
is a discrepancy between the enantiomers in the rate of the decay of Ca++ signals
subsequent to the administration of 10µM of the respective enantiomer. While the
signal subsequent to administration of 10µM (R)-N-Me 4-Me AMPH tends to
decay relatively quickly and independently of concentration, the signal
subsequent to 10µM (S)-N-Me 4-Me AMPH tends to decay more slowly at a
higher concentration of compound. This phenomenon is reminiscent of the
persistent current, an electrophysiological phenomenon observed in oocytes and
HEK cells in a time- and concentration-dependent manner after administration of
(S)-amphetamine, and not after administration of (R)-amphetamine. After taking
the first derivative of the mean of the value of each point in time for both 10µM
(R)- and (S)-N-Me 4-Me AMPH at hDAT, the mean value of the negative slope
over the interval 55.01 to 56.01 seconds for (R)-N-Me 4-Me AMPH (-.0338) is
about 3-fold larger than the value of the negative slope over the same interval for
(S)-N-Me 4-Me AMPH (-.0121). Please see Figures 9 and 10. The De Felice lab
is very interested in the ionic and mechanistic components of the persistent
current, and these results, obtained via a novel assay, bolster the
electrophysiological relevance of this subtype of transporter current.
The finding that N-alkyl 4-Me AMPH alkyl chain extension from N=1 to
N=2 switches an hDAT substrate to an hDAT inhibitor is incredibly stimulating;
furthermore, the fact that this switch occurs in hDAT and not in hNET adds to the
allure of the phenomenon. Curious of the mechanistic basis of this finding, I was
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led to a 2015 paper by Jacob Andersen and colleagues. This group has found
that differential S1 site residues—defined as residues within 8Å of bound
substrate—between hDAT and hNET control the transporter specificity of
pharmacological inhibitors. There are 6 such residues. Specifically, this group
finds that mutation of these 6 differential residues of hNET to the corresponding
residues of hDAT gives rise to a mutant construct at which hDAT-selective
inhibitors are 900-fold more potent. The converse does not hold: mutation of
these 6 differential residues of hDAT to the corresponding residues of hNET
gives rise to a mutant construct at which hNET-selective inhibitors are, at most,
26-fold more potent.
Thus, I conjectured that differential S1 site residues between hDAT and
hNET might mediate the differential pharmacology of 4-Me N-Et AMPH. Viewing
a sequence alignment in which all differential S1 site residues are indicated, I
observed that, of these 6 differential residues between hDAT and hNET, the
dopamine transporter of Drosophila melanogaster (dDAT) shares 5 of the 6 with
hNET. Please see Figure D1. I then reasoned that N-Et 4-Me AMPH might
function as a dDAT substrate, especially since it is known that, in general, dDAT
exists as a primordial hybrid with hDAT- and hNET-like characteristics (Pörzgen
et al., 2001). The results of the TEVC trace of Figure 22 support my hypothesis:
(S)-N-Et 4-Me AMPH is a moderately efficacious substrate of dDAT. Of note, (S)N-Et 4-Me AMPH gives rise to both an off-spike, which in Figure 22 is more
evident upon the cessation of the 5µM control pulse of dopamine, and a
persistent current. Both of these phenomena are typical features of substrates at
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dDAT, while the persistent current is typical of amphetamine substrates with the
(S) absolute configuration at dDAT and hDAT. The off-spike likely represents the
final permeation of Na+ cations that, pushed to the periphery by the permeating
substrate molecules, pierce through the transporter just as its channel-like mode
of function is switching off. Interestingly, dDAT demonstrates stereoselectivity in
its affinity for the enantiomers of N-Me 4-Me AMPH (Figure 21). (S)-N-Me 4-Me
AMPH gives rise to about 5 times more current flux at dDAT than does (R)-N-Me
4-Me AMPH. This differential affinity between enantiomers of AMPH and AMPH
analogs is a characteristic feature of hDAT and not of hNET (compare Figures 6
and 14).

Figure D1: sequence alignment of dDAT, hDAT, and hNET. Differential S1
site residues between hDAT and hNET are highlighted in yellow. Note that
of these 6 differential residues between hDAT and hNET, 5 of the 6 are
equivalent between dDAT and hNET. Adapted from Andersen et al., 2015.
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Expanding on the idea that differential S1-site residues mediate intertransporter differences in the pharmacodynamics of 4-Me N-Et AMPH, the lab of
Dr. Jacob Andersen kindly donated a sample of their construct in which the 6
differential S1 site residues of hDAT are mutated to the corresponding residues
of hNET. After confirming the identity of the construct by restriction gel analysis, I
expressed it in HEK293 cells for assay in a typical substrate trial of the Ca++
fluorescence assay. Unfortunately, only very faint signals were evident in
response to the control pulse of 10µM dopamine, and uptake of APP+, a
fluorescent monoamine transporter substrate, was distinct but quite minor (data
not shown). Thus, at least two conclusions emerge: 1.) The electrogenicity of the
mutant protein has been compromised. No one has assessed these mutants for
current before, as the Andersen lab performed only uptake studies, so it is
possible that the mutation of such crucial residues has abrogated the
electrogenic capability of the construct. Further, this particular construct
demonstrates a reduction in uptake by about 50% compared to the wildtype
hDAT (Andersen et al., 2015). 2.) Not enough protein was expressed. I plan to
expand on this experiment in the future, perhaps by subcloning the construct to
an oocyte expression vector for TEVC experiments.
From our N-SIM super-resolution microscopic studies, it is evident that, in
general, hDAT and mVenus-Cav1.2- tend to occupy exclusive domains within the
plasma membrane; moreover, this exclusivity of domain is a virtually inviolable
rule during the processes of intracellular protein trafficking (please see Figures 3
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and 5). However, unmistakably there are domains within the membrane at which
the proteins are apposed so closely that they are unresolvable individually.
Although the engineered nature of the expression of mVenus-Cav1.2 and
hDAT limits the power of conclusion, it is interesting to conjecture that functional
crosstalk between the monoamine transporters and L-type Ca++ channels obtains
in vivo. In support of this concept, Gnegy et al. (2004) use simultaneous wholecell patch-clamp and amperometric recording of HEK cells stably expressing
hDAT. This group shows that when the membrane-impermeant Ca++ chelator
BAPTA is added to the intracellular pipette solution—thus buffering any
intracellular spikes in Ca++—the mean hDAT-mediated oxidative current induced
by application of 10µM (S)-amphetamine is significantly reduced compared to
control. Thus it is argued that transient increases of the intracellular
concentration of Ca++ are implicated in the mechanism of amphetamine-induced
dopamine efflux via hDAT. N-Me amphetamine is also known to release Ca++
from intraceullular stores, at potency 2-fold greater than that of (S)-amphetamine,
and via a calmodulin-dependent protein kinase II (CaMKII)- and PKC-dependent
mechanism (Goodwin et al., 2008).
It is conceivable that functional crosstalk between hDAT and Cav1.2 or
Cav1.3 gates forms of synaptic homeostasis via induction of Ca++-mediated
downstream cellular events; in fact, this built-in feedback mechanism would
represent an elegant means for the presynaptic neuron to gauge its own activity
level. In support of the basic plausibility of this proposition, Liu et al. (2014),
recording from brain slices of the mouse ventral tegmental area, demonstrate
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that Cav1.2 and Cav1.3 are crucial drivers of the burst mode of firing within
dopaminergic neurons. In conjunction with this finding of Liu et al. (2014), it is
known that amphetamine and methamphetamine give rise to D1 receptoractivated PKA-mediated increases in the phosphorylation and the resulting
activity of L-type Ca++ channels, and this pathway is proposed to be involved in
amphetamine-induced behavioral sensitization (Rajadhyaksha and Kosofsky,
2005). Thus it is apparent that L-type Ca++ channels have at least one
mechanism of sensing DAT substrates. It is interesting to speculate that neuronal
L-type Ca++ channels may be able to sense psychomotor stimulant administration
more directly, by reacting to heightened, stimulant-induced hDAT ionic
throughput.
Relatedly, Kantor (2004) find that rat pheochromocytoma PC12 cells
repeatedly exposed to 1µM amphetamine show a significantly elevated
dopamine efflux in response to experimental exposure to 1µM amphetamine
compared to cells repeatedly exposed to vehicle. Upon exposure to L- and Ntype Ca++ blockers, the PC12 cells intermittently exposed to 1µM amphetamine
yield significantly reduced dopamine efflux compared to PC12 cells not exposed
to these Ca++ channel blockers. Expanding in cultured neurons, Vaarman et al.
(2010) report a voltage-gated Ca++ channel-dependent increase in the
intracellular concentration of Ca++ after exposure of neurons to 20µM dopamine,
and this increase is D1- and D2-receptor independent and abolished by
concomitant administration of 20µM GYKI-52895, a selective DAT blocker.
However, the elevation of intracellular Ca++ often occurs over long scales of time,
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on the order of minutes, and future experimental work must elaborate on the
mechanisms underlying the findings of Vaarman et al. (2010).
The results of this study also represent progress toward the optimization
of the Ca++ fluorescence assay at hNET, which tends to display anomalous
behavior during experiments at hNET. During experiments using Cav1.2 as a
reporter for hNET-mediated current flux, there are cases in which welltransfected and healthy cells fail to evolve drug-induced Ca++ signals. This
curious effect may be due to a more diminutive unitary current via hNET
compared to via hDAT and hSERT, which, under the same circumstances,
reliably evolve Ca++ signals. Or, the biophysics of hNET could be inherently out
of phase with the biophysics of Cav1.2, such that in general, there is a lower
probability of current permeation through hNET coupling to the voltage-sensing
domain of Cav1.2. Thus, we decided to use Cav1.3 as the reporter for hNET. It,
too, proved problematic, as Cav1.3 tends to fire sporadic, rhythmic action
potentials when over-expressed. Optimizing, we found that: no more than .5µg of
Cav1.3 plasmid per 24 wells can be used. Further, it is extremely important not to
overplate the hNET initially. Proper plating—30-40% confluency—is required.
Future work must continue to optimize this method to the level exhibited by the
hDAT and hSERT versions of the assay, which can rightfully be called highthroughput.
The Ca++ fluorescence assay, and, as mentioned, especially its highthroughput level versions, represent an assay with a host of distinct advantages
over the traditional methods of two-electrode voltage clamp (TEVC) and the
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synaptosome. Clearly, there are disadvantages inherent to the Ca++ fluorescence
assay as well. Please see Table 4 for a synopsis of the advantages and
disadvantages between the Ca++ fluorescence assay and TEVC. In particular, the
Ca++ fluorescence assay represents a gain of reliability: one can be certain one
will derive data from a given experiment. Regarding oocytes, especially when
intending to study hDAT, there is no such security. Further, it is quite the
advantage to be able to study hNET, which, for mysterious reasons, has never
expressed in oocytes. The disadvantages of the Ca++ fluorescence assay are
obvious: the scientist is not studying the monoamine transporters, the main
proteins of interest, directly, but rather is led to inferences based on the activity of
a reporter protein. This once-removal from the primary object of study is a distinct
disadvantage to pure biophysics, but not to pharmacology, since the propensity
of a substrate to couple to L-type Ca++ channel currents has been shown to be
“dominated by the affinity of the substrate at [the transporter]” (Cameron et al.,
2015). Relative to synaptosomes, the Ca++ fluorescence assay also offers a
reprieve from technical manipulation and preparation of ex vivo tissue
specimens. Again, its relative disadvantages are obvious: for example, one
cannot measure the propensity of substrates to function as releasers of tritiated
monoamines. However, it is possible to study uptake inhibition by means of
measuring the potency of inhibitors to retard the uptake of APP+.
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Advantages:
1.) Dependability
• Permanent cell lines eliminate oocyte inter-batch variability.
• Permanent cell lines reliably express transporters after fixed
interval of ~72 hours; hDAT oocytological expression
requires 6-10 days.
2.) Ease of preparation
• No requirement for technical nanoliter cRNA injection.
• HEK cells plated and transfected under sterile conditions,
eliminating loss of oocytes to contamination.
3.) Ability to assay hNET
• hNET has been refractory to expression in oocytes.
4.) Streamlined data analysis
• Data acquisition stereotyped in time dimension.
5.) Exquisite sensitivity to high affinity compounds
• Signals are perceptible at drug concentrations as low as
1nM.
6.) Visual feedback
• Failed trials are obvious, successful trials aesthetically
pleasing.
Disadvantages:
1.) No direct measure of inhibition
• Transporter inhibition manifests as hyperpolarizing current in
oocyte TEVC assay.
2.) Fundamentally a surrogate measure
• Calcium ratiometry is a reporter of transporter-mediated
current.
Table 4: Advantages and disadvantages of the calcium
fluorescence assay versus the oocyte two-electrode voltage clamp
(TEVC) assay for the study of monoamine transporter function.
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VI. Conclusion
In conclusion, and as evidenced by the results of the present study, the
Ca++ fluorescence assay represents a means for rapid data acquisition,
streamlined data analysis, and efficient pharmacological profiling of interesting
compounds. By means of this assay we discovered that N-Me 4-Me AMPH Nalkyl chain extension exerts differential pharmacodynamic effects at hDAT and
hNET: N-Me to N-Et N-alkyl chain extension takes a substrate to an inhibitor at
hDAT, and both compounds are substrates at hNET (Figure 20). Furthermore,
S1 site residue conservation between dDAT and hNET correlates with
pharmacodynamic effects of (S)-N-Et 4-Me AMPH (Figures 22 and D1). Finally,
our immunostaining studies demonstrate that there exist cell membrane domains
of close apposition of hDAT and mVenus-Cav1.2, yet the two proteins apparently
traffic via different intracellular routes (Figures 3, 5).
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